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ABSTRACT 
 
THE MULTIFUNCTIONAL PROTEIN DAXX: STUDIES OF ITS BIOLOGY AND REGULATION, 
AND DISCOVERY OF A NOVEL FUNCTION 
 
Trisha Agrawal 
Xiaolu Yang, PhD 
  
 Daxx, a multifunctional protein with a diverse set of proposed functions, is 
ubiquitously expressed and highly conserved through evolution. A primarily nuclear 
protein, Daxx is able to regulate apoptosis, transcription, and cellular proliferation. 
Despite many studies into the function of Daxx, its precise role in the cell remains 
enigmatic. Herein, evidence is presented to expand upon the known anti-apoptotic 
function of Daxx, to establish Daxx as a novel molecular chaperone, and to further its 
repertoire of transcriptional targets.  As an apoptotic inhibitor, Daxx is known to regulate 
p53 by stabilizing its main negative regulator, Mdm2, via formation of a ternary complex 
between Daxx, Mdm2, and Hausp. The present study reveals that DNA damage-induced 
phosphorylation of Daxx is an important step in the disruption of the Daxx-Mdm2-Hausp 
complex, allowing for p53 activation. A novel activity for Daxx is presented whereby it is 
able to modulate protein folding in vitro and in vivo. Daxx can refold and reactivate 
denatured substrates using its paired amphipathic helical and acid-rich domains. This 
finding was extended to p53, where Daxx was able to solubilize misfolded p53 both in 
vitro and in vivo. Further, this finding may provide a biochemical rationale as to the 
varied functionality of Daxx in the cell. Finally, a novel transcriptional target, Cdk6, is 
described for Daxx. Microarray analysis indicated that Cdk6 is a strongly downregulated 
gene upon Daxx silencing. Depletion of Daxx in various cancer and primary cell lines led 
to a decrease in Cdk6 protein levels. Additionally, Daxx can affect transcription of Cdk6, 
vii 
 
and chromatin immunoprecipitation reveals that Daxx binds to the Cdk6 promoter. 
Together, these results indicate that Daxx has potential functional plasticity and is 
involved in an array of cellular functions; in fact, cellular homeostasis relies on the proper 
execution of multiple biological processes. Elucidation of the biology of Daxx would not 
only provide insight into the regulation of these processes, but may also establish Daxx 
as a relevant therapeutic target.  
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CHAPTER 1:  INTRODUCTION 
Daxx 
 The multifunctional protein Daxx (death domain-associated protein) has been 
implicated in apoptosis, transcription, and cellular proliferation. Despite extensive study 
into its function, its precise role in the cell is unclear and encompasses a seemingly 
divergent set of proposed activities. This dissertation aims to further understand the 
biological role of Daxx and the following section will give an overview regarding the 
structure, subcellular localization, and known functions of Daxx.  
Discovery and Structure 
 Daxx was first identified by a yeast two-hybrid screen as an adaptor protein for 
the intracellular portion of the death receptor, Fas (CD95/Apo-1), and potentiates Fas-
induced apoptosis via the c-Jun N-terminal kinase (JNK) pathway (Yang, Khosravi-Far, 
et al, 1997). Human Daxx is a protein of 740 amino acids and has no significant 
homology to known proteins. It is ubiquitously expressed with especially high expression 
in the testes (Kiriakidou, Driscoll, et al, 1997; Yang, Khosravi-Far, et al, 1997). Daxx is 
poorly characterized at the structural level; however, among known domains it contains 
two N-terminal paired amphipathic helical domains, a coiled-coil domain, an acid-rich 
(D/E) domain, and a C-terminal Serine/Proline/Threonine-rich domain (Figure 1.1). Daxx 
also contains two SUMO-interacting motifs (SIMs), one each within its N- and C-
terminus, which are important for its subcellular localization and association with other 
proteins (Escobar-Cabrera, Okon, et al, 2011; Lin, Huang, et al, 2006; Ryu, Chae, and 
Kim, 2000; Santiago, Godsey, et al, 2009).  
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Figure 1.1. Schematic depicting structural domains within Daxx.  
PAH – paired amphipathic helices; CC – coiled coil domain; D/E – acid-rich region; 
S/P/T – serine/proline/threonine-rich region. Asterisks indicate SUMO-interacting motifs.  
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Cellular Localization 
 Subsequent to its initial discovery as a cytoplasmic protein, many studies 
emerged confirming the cytoplasmic localization of Daxx and validating its pro-apoptotic 
function (Chang, Nishitoh, et al, 1998; Gongora, Stephan, et al, 2001; Ko, Kang, et al, 
2001; Lalioti, Vergarajauregui, et al, 2002; Perlman, Schiemann, et al, 2001). In the 
cytoplasm, Daxx associates with the apoptosis signaling kinase 1 (ASK1) and this 
association can be inhibited by heat shock protein 27 (Hsp27) (Chang, Nishitoh, et al, 
1998; Charette, Lavoie, et al, 2000; Ko, Kang, et al, 2001; Song, and Lee, 2003). 
Despite evidence of Daxx being a pro-apoptotic protein residing mainly in the cytoplasm, 
it later became clear that Daxx is predominantly a nuclear protein, which may be 
translocated to the cytoplasm in response to certain stimuli; for example, FAS 
stimulation and glucose deprivation (Lindsay, Giovinazzi, and Ishov, 2009; Song, and 
Lee, 2004; Yang, Khosravi-Far, et al, 1997).  
In the nucleus, Daxx localizes in promyelocytic leukemia-nuclear bodies (PML-
NBs), macromolecular complexes that regulate a variety of cellular processes including 
tumor suppression and transcriptional repression (Bernardi, and Pandolfi, 2007; Li, Leo, 
et al, 2000; Torii, Egan, et al, 1999; Zhong, Salomoni, et al, 2000). An essential 
component of PML-NBs is the PML protein, which when SUMOylated, is recognized by 
the C-terminal SIM on Daxx and leads to the accumulation of Daxx at PML-NBs (Ishov, 
Vladimirova, and Maul, 2004; Lin, Huang, et al, 2006). Daxx displays aberrant 
localization in acute promyelocytic leukemia (APL) cells, where the PML-NB structure is 
disrupted (Zhong, Salomoni, et al, 2000). Daxx recruitment to PML-NBs is important for 
many of its functions including apoptotis and transcription (Li, Leo, et al, 2000; Torii, 
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Egan, et al, 1999). For example, in PML -/- B-lymphocytes, apoptosis is impaired due to 
the delocalization of Daxx from the PML-NBs (Zhong, Salomoni, et al, 2000).  
 In addition to its accumulation at PML-NBs, Daxx is localized to heterochromatin 
in a cell cycle-dependent manner (Hollenbach, McPherson, et al, 2002; Ishov, Sotnikov, 
et al, 1999; Ishov, Vladimirova, and Maul, 2004). This localization occurs via the 
association of Daxx with the α-thalassemia/mental retardation syndrome protein (ATRX), 
a putative member of the SNF2 family of ATP-dependent chromatin remodeling proteins 
(Tang, Wu, et al, 2004; Xue, Gibbons, et al, 2003). The N-terminus of Daxx interacts 
with ATRX and this association depends upon the phosphorylation of ATRX (Ishov, 
Vladimirova, and Maul, 2004). Ishov, et al found that Daxx and ATRX associate at PML-
NBs during most of interphase. Daxx then leaves the PML-NBs and is actively recruited 
to heterochromatin during late S phase via association with phosphorylated ATRX and 
loss of Daxx leads to prolongation of S phase of the cell cycle (Ishov, Vladimirova, and 
Maul, 2004). Until recently, there was no explanation as to why Daxx would associate 
with heterochromatin during such a short window of time during the cell cycle. The newly 
discovered function of Daxx as a histone chaperone may shed light on this phenomenon 
and will be discussed in a later section.  
Function 
Apoptosis 
 Daxx initially appeared to be a pro-apoptotic protein; however, several lines of 
evidence indicate that Daxx may also have an anti-apoptotic function. Disruption of the 
Daxx gene in mice leads to embryonic lethality before E8.5 (Michaelson, Bader, et al, 
1999). Daxx -/- embryonic stem (ES) cells show higher rates of spontaneous apoptosis, 
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suggesting that Daxx has an anti-apoptotic role that is important during development. 
Further, Daxx silencing in various cell lines sensitizes cells to apoptotic stimuli, verifying 
Daxx as an important anti-apoptotic modulator (Chen, and Chen, 2003; Michaelson, and 
Leder, 2003).  
 Additionally, research from our lab shows that Daxx has a critical role in 
regulating the tumor suppressor p53 by stabilizing mouse double minute 2 (Mdm2), the 
major p53 negative regulator (Tang, Qu, et al, 2006). Daxx forms a complex with Mdm2 
and herpesvirus-associated ubiquitin-specific protease (Hausp) that serves to stabilize 
Mdm2, leading to the ubiquitination and degradation of p53 (Figure 1.2). Upon DNA 
damage, the Daxx-Mdm2-Hausp complex dissociates, resulting in Mdm2 degradation 
and allowing for the activation of p53-mediated apoptosis. The disruption of this complex 
is mediated by the protein kinase ATM (ataxia telangiectasia mutated); how ATM 
mediates the dissociation of the complex is the focus of chapter two.  
Transcriptional Regulation 
Due to the localization of Daxx to the nucleus, and in particular heterochromatin, 
several groups have focused their efforts on uncovering a possible role for Daxx in 
transcriptional regulation. Daxx has a diverse array of binding partners and many of 
these include transcription factors. Generally, Daxx is a transcriptional repressor as 
shown by its ability to repress the activity of several transcription factors including Pax3, 
ETS1, p53 and p73, NF-κB, CREB, glucocorticoid receptor, and HDAC2, among others 
(Gostissa, Morelli, et al, 2004; Huang, Chang, et al, 2012; Kim, Park, and Um, 2003; 
Lehembre, Muller, et al, 2001; Li, Leo, et al, 2000; Morozov, Massoll, et al, 2008; Park, 
Lee, et al, 2007). The transcriptional repressive activities of Daxx have been linked to its  
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Figure 1.2. Illustration depicting role of Daxx in Mdm2 and p53 stability.  
In unstressed cells, Daxx bridges the interaction between Hausp and Mdm2, preventing 
Mdm2 ubiquitination. Upon induction of DNA damage, the complex dissociates leading 
to Mdm2 degradation and p53-mediated apoptosis and p21 transcription. 
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association with ATRX and its delocalization from PML-NBs (Newhart, Rafalska-Metcalf, 
et al, 2012). PML can inhibit Daxx-mediated transcriptional repression via direct binding 
to Daxx and by subsequent recruitment of Daxx to PML-NBs. In PML -/- cells, Daxx 
forms aggregates around condensed chromatin, where it may exert its repressive 
activities (Zhong, Salomoni, et al, 2000). Daxx can also activate transcription of a few 
transcription factors, for example, Pax5 and HSF1, albeit under very specific cellular 
conditions (Boellmann, Guettouche, et al, 2004; Emelyanov, Kovac, et al, 2002). 
 Related to its activity as a transcriptional regulator, recent studies have 
implicated Daxx as a histone chaperone for the histone 3 (H3) variant, H3.3 (Drane, 
Ouararhni, et al, 2010; Elsaesser, and Allis, 2010; Lewis, Elsaesser, et al, 2010).  Unlike 
the other H3 variants, H3.1 and H3.2, H3.3 is expressed throughout the cell cycle and is 
incorporated in chromatin in a replication-independent manner (Elsaesser, Goldberg, 
and Allis, 2010; Wu, Tsai, and Bonner, 1982). H3.3 is believed to be an important carrier 
of genetic information and while it was initially found solely at euchromatin, it has been 
shown to associate with regulatory elements and constitutive chromatin at telomeres 
(Lewis, Elsaesser, et al, 2010; Salomoni, 2013). Prior to the discovery of Daxx as a 
histone chaperone, the interaction between ATRX and H3.3 was considered to be 
essential for the maintenance of telomere structural integrity (Wong, McGhie, et al, 
2010). Subsequent to this, two groups independently found that Daxx also associates 
specifically with H3.3 via the central domain of Daxx (Drane, Ouararhni, et al, 2010; 
Goldberg, Banaszynski, et al, 2010; Lewis, Elsaesser, et al, 2010). In accordance with 
its subcellular localization, Daxx was found in both cytoplasmic and nuclear H3.3 
complexes. While Daxx alone was able to assemble chromatin in vitro, the deposition of 
H3.3 onto telomeres was dependent upon the formation of the Daxx-ATRX complex. 
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This Daxx-ATRX-dependent targeting of H3.3 to telomeres appears to suppress 
transcription over telomeric repeats in ES cells (Goldberg, Banaszynski, et al, 2010). 
Conversely, the deposition of H3.3 on pericentric heterochromatin by Daxx and ATRX 
leads to a greater abundance of mRNA transcripts at these regions (Drane, Ouararhni, 
et al, 2010). The role of H3.3 deposition is unclear, but the function of Daxx as a H3.3 
chaperone provides a potential mechanism for its transcriptional regulatory activity. 
Indeed, a recent study shows that in neuronal cells, the deposition of H3.3 at a subset of 
immediate early genes (IEGs; Bdnf Exon IV, c-Fos, Egr2, and Dusp6) relies mainly on 
Daxx, leading to increased transcriptional induction of these genes (Michod, Bartesaghi, 
et al, 2012). It is clear that Daxx has the ability to regulate transcription but it is still 
nebulous if this regulation is inhibitory or activating. A novel transcriptional target of 
Daxx, Cdk6, will be explored in chapter four.  
Cellular Proliferation and Cancer 
Due to the interaction of Daxx with multiple proteins and the varying 
consequences of these interactions, it is plausible that Daxx has proliferative effects that 
may be mediated via its influence on apoptosis, transcription, p53 regulation, or histone 
chaperone activity. These effects may regulate the promotion of cancer and/or 
tumorigenesis. In fact, many groups have found that Daxx is involved in cellular 
proliferation and in turn, cancer progression. As previously discussed, Daxx can stabilize 
Mdm2 leading to the ubiquitination and degradation of p53. Depletion of Daxx in cells 
leads to greater apoptosis in an Mdm2- and p53-dependent manner (Tang, Qu, et al, 
2006). This observation has led other groups to identify Daxx as an important modulator 
of p53 in cancer. Two studies from the same group indicate that Daxx is important for 
ovarian cancer progression (Pan, Yi, et al, 2013; Pan, Zhou, et al, 2013). They reported 
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that Daxx mRNA and protein levels were overexpressed in ovarian cancer cells lines 
and ectopic expression of Daxx led to increased ovarian cancer cell proliferation, 
migration, colony formation, and chemoresistance; depletion of Daxx had the converse 
effect. Additionally, transplantation of stable cells overexpressing Daxx into nude mice 
was capable of forming metastatic tumors. Daxx silencing led to enhanced senescence 
in mouse ovary surface epithelial (mOSE) cells in a p53/p21-dependent manner. In 
another study using pediatric acute lymphoblastic leukemia (ALL) cells, a 
pharmacological intervention was used to disrupt the Daxx-Mdm2-Hausp complex. The 
group found that Berberine, a potential herbal chemotherapeutic, was able to decrease 
Daxx transcription and protein levels, which led to reduced formation of the Daxx-Mdm2-
Hausp complex. This allowed for p53 activation and greater cell death of the ALL cells 
(Zhang, Gu, et al, 2010). 
 The role of Daxx as a histone chaperone has also proven to be important for 
certain cancers, including pancreatic neuroendocrine tumors (PanNETs) and pediatric 
glioblastoma multiforme (GBM) (de Wilde, Edil, et al, 2012; Zhang, Francois, et al, 
2013). When the exome of primary PanNETs was sequenced, somatic mutations in the 
genes encoding Daxx and ATRX were found in 42.6% of the PanNETs. There were 
mutually exclusive mutations in Daxx and ATRX, consistent with their presumptive 
cooperation in transcription and histone chaperone activity. Interestingly, patients with 
mutations in Daxx or ATRX had prolonged survival rates compared to patients without 
mutations in these genes (Jiao, Shi, et al, 2011). Due to the role of Daxx and ATRX in 
chromatin remodeling at telomeres, Heaphy, et al examined the status of telomeres in 
patients with PanNETs that contained mutations in Daxx or ATRX. A perfect correlation 
between loss of ATRX or Daxx function and the presence of alternative lengthening of 
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telomeres (ALT) was observed (Heaphy, de Wilde, et al, 2011). Further, mutations in 
Daxx and ATRX have been found in cases of pediatric GBM. A recent study showed that 
mutations in Daxx or ATRX were found in 31% of the tumor samples analyzed, and in 
100% of samples that also harbored mutations in the gene that codes for H3.3, H3F3A 
(Schwartzentruber, Korshunov, et al, 2012). Again, a mutation in Daxx or ATRX was 
strongly correlated with the presence of the ALT phenotype (Schwartzentruber, 
Korshunov, et al, 2012). Although a mechanism for how Daxx and ATRX cooperate to 
cause ALT has not been proposed, it is logical to posit that their histone chaperone and 
chromatin remodeling activities are intimately linked to this phenotype. 
 Daxx has also been implicated in a few scenarios of cancer using novel 
pathways of action. One such instance is the interaction of Daxx with RAS-association 
domain family protein 1A (Rassf1A).  In human breast cancer cells with experimentally 
reduced Daxx, the cells display resistance to taxol, a microtubule-destabilizing agent 
commonly used as a chemotherapeutic. In Daxx-depleted cells, there is a prolonged 
stabilization of cyclin B leading to faster progression through prophase but a lengthening 
of prometaphase/metaphase, when Daxx and Rassf1A are found to interact. In cells that 
respond to taxol therapy, taxol induces mitotic block creating micronucleated cells that 
are incapable of proliferation. In Daxx- and Rassf1A-depleted cells, the accumulation of 
cyclin B allows for cells to reenter mitosis after mitotic block is induced making them 
resistant to taxol, whereas breast cancer cells expressing high levels of Daxx exhibit a 
robust response to taxol (Giovinazzi, Lindsay, et al, 2012). Additionally, Daxx expression 
is often upregulated in prostate cancer cells and is positively correlated with Gleason 
score and metastasis. Daxx can induce chromosome instability in these cells via 
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inhibition of the anaphase-promoting complex (APC), leading to chromosomal polyploidy 
during prostate cancer development (Kwan, Lau, et al, 2013). 
Scope of Dissertation 
 There is great ambiguity regarding the biology of Daxx in the cell. In this 
dissertation, I examine three distinct functions of Daxx that further elucidate the various 
processes in which Daxx is involved. First, I expand the previously found role of Daxx in 
p53 regulation by finding that phosphorylation of Daxx by ATM upon DNA damage leads 
to dissociation of the Daxx-Mdm2-Hausp complex in chapter two. Second, I uncover a 
novel role for Daxx in protein folding, whereby Daxx is able to refold and recover the 
activity of denatured substrates in chapter three. Finally, I briefly investigate if Daxx can 
regulate the cell cycle via a specific cyclin-dependent kinase (Cdk), Cdk6, in chapter 
four. The following sections of this chapter will provide brief introductions into the major 
biological themes of each of these projects: the mutual regulation between Mdm2 and 
p53, an overview of protein quality control in mammalian cells, and an outline of cell 
cycle progression.  
The Mdm2-p53 Feedback Loop 
 The tumor suppressor p53 is one of the most extensively studied proteins as 
evidenced by the sheer number (over 60,000 as of 2012) of publications centering on its 
function and regulation. Its study has proven to be invaluable as more than 50% of 
human tumors harbor mutations in p53 itself or p53 effector proteins (Vogelstein, Lane, 
and Levine, 2000). Deletion of p53 in mice does not lead to embryonic lethality or 
developmental defects but does predispose the mice to spontaneous lymphomas and 
sarcomas by 2.5 months of age, leading to death by 6 months of age (Donehower, 
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Harvey, et al, 1992). 95% of malignant mutations of p53 are missense mutations found 
in the DNA-binding domain (DBD) (Greenblatt, Bennett, et al, 1994; Pavletich, 
Chambers, and Pabo, 1993). A proportion of these mutations lead to structural instability 
of p53 (Ang, Joerger, et al, 2006). It is known that mutant p53 often acts as a dominant-
negative due to the formation of mixed tetramers, which contain both wild-type and 
mutant p53, abrogating the transcriptional effects of wild-type p53 (Chan, Siu, et al, 
2004). A recent study suggests that structurally destabilized mutant p53 has greater 
aggregation propensity, which induces misfolding in wild-type p53 and thereby 
decreases the concentration of functional p53 in the cell (Xu, Reumers, et al, 2011).  
In the cell, p53 levels are tightly controlled by its continuous ubiquitination and 
degradation, a process predominantly mediated by Mdm2 (Momand, Wu, and Dasgupta, 
2000). In response to various stresses, such as DNA damage and oncogene activation, 
p53 is activated, which leads to the transcription of anti-proliferative genes. These 
effector proteins include pro-apoptotic (Bax and Apaf-1, e.g.), cell cycle arrest (p21, e.g.) 
or cellular senescence (p21 and PML, e.g.) promoting factors (Figure 1.3) (Vogelstein, 
Lane, and Levine, 2000). p53 is heavily post-translationally modified upon its activation, 
leading to conformational changes within the protein allowing for it to become a 
transcriptional activator. p53 is acetylated, methylated, ubiquitinated, and SUMOylated. 
The extent and type of modification depends on the cellular context (Gu, and Zhu, 2012). 
The N-terminus of p53 is extensively phosphorylated, including its phosphorylation by 
ATM and Chk2 at Ser15 and Ser20, respectively, upon DNA damage (Banin, Moyal, et 
al, 1998; Hirao, Kong, et al, 2000). One of the most important modifications that occurs 
on p53 is Mdm2-mediated ubiquitination (Gu, and Zhu, 2012).  
Mdm2 is an E3 ubiquitin ligase not only for p53, but also for itself (Fang, Jensen, 
et al, 2000; Fuchs, Adler, et al, 1998). The Mdm2 gene was originally cloned from the  
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Figure 1.3. The p53 response.  
Upon the induction of various stress signals, p53 levels are stabilized leading to the 
activation of different downstream regulators. The net effect of these regulators is to 
inhibit cell growth, ultimately preventing tumorigenesis. Reproduced with permission 
(Vousden, and Lu, 2002). 
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3T3-DM transformed mouse cell line, where it was gene-amplified on double-minute 
chromosomes (Fakharzadeh, Trusko, and George, 1991). Ensuing discoveries 
established the importance of Mdm2 as a p53 negative regulator not only via its ubiquitin 
ligase activity, but also due to its direct binding to the N-terminus of p53 and subsequent 
inhibition of p53 transcriptional activity (Chen, Marechal, and Levine, 1993; Kubbutat, 
Jones, and Vousden, 1997; Momand, Zambetti, et al, 1992). In an unstressed cell, 
Mdm2 associates with p53, targeting it for degradation (Figure 1.4). Upon the induction 
of DNA damage, for example, the Mdm2-p53 complex is disrupted through the 
accumulation of post-translational modifications on both p53 and Mdm2. 
Phosphorylation of Mdm2 by ATM inhibits its E3 ligase activity due to the disruption of 
higher-order Mdm2 oligomers that are necessary for its activity (Cheng, Chen, et al, 
2009). The dissociation of p53 from Mdm2 allows p53 to avoid degradation and act as a 
transcriptional activator. Intriguingly, the Mdm2 gene is also a direct transcriptional target 
of p53, whereby Mdm2 levels increase in response to p53 transactivation (Figure 1.4) 
(Barak, Juven, et al, 1993; Picksley, and Lane, 1993; Wu, and Levine, 1997). The 
importance of the negative feedback loop between Mdm2 and p53 is underscored by the 
finding that though mdm2 -/- mice are embryonic lethal, this lethality can be rescued via 
simultaneous deletion of the p53 gene (Jones, Roe, et al, 1995; Montes de Oca Luna, 
Wagner, and Lozano, 1995). This finding indicates that the main role of Mdm2 during 
development is to restrain the apoptotic activity of p53 and that a hyperactive p53 in 
incompatible with animal survival. Additionally, 7% of human tumors have gene 
amplification or aberrant expression of Mdm2 and Mdm2 overexpression and p53 
mutations are generally mutually exclusive (Wade, Li, and Wahl, 2013). It is clear that 
the mutual regulation of p53 and Mdm2 is critical for cell viability as perturbations in this 
system can lead to human malignancies. Understanding the critical regulators of  
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Figure 1.4. The p53-Mdm2 feedback loop.  
In an unstressed cell, Mdm2 targets p53 for degradation in the 26S proteasome via 
ubiquitination. Upon the induction of stress, p53 is activated and transactivates Mdm2. 
Mdm2 then ubiquitinates p53 preventing further gene transactivation. This, in turn, forms 
a feedback loop between Mdm2 and p53. Reproduced and modified with permission 
(Murray-Zmijewski, Slee, and Lu, 2008). 
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these two proteins is essential and will be the focus of chapter two.  
Protein Quality Control 
 The proper functioning of the cell relies on correct protein folding. There are 
approximately 20,000 proteins involved in the biological processes of the cell and for 
most of these the acquisition of a three-dimensional structure is a requirement for 
biological activity (Dobson, 2003). Protein folding in the cell can occur in various 
compartments. For example, during translation of proteins from the ribosome, protein 
folding occurs co-translationally as regions of the nascent polypeptide chain begin to fold 
before synthesis of the entire protein (Hardesty, and Kramer, 2001). Other proteins may 
undergo the majority of their folding in the cytoplasm after release from the ribosome, 
while others may fold in specific compartments such as the endoplasmic reticulum (ER) 
or mitochondria (Hartl, and Hayer-Hartl, 2002). During these folding processes, it is likely 
that portions of a nascent polypeptide will be exposed in partially folded, aggregation-
prone states for considerable periods of time. Additionally, proteins folding during 
translation or in other compartments will be subject to the crowded intracellular milieu, 
strongly increasing the probability of non-native proteins to aggregate (Ellis, 2001; Ellis, 
and Minton, 2006). Moreover, errors in protein folding naturally occur due to genetic 
mutations or protein damage caused by cellular stress. Thus, the cell must maintain a 
proteostasis network to contend with these issues as the proper folding of a protein is 
not only important for its biological activity, but also for general cellular viability as the 
failure of proteins to fold properly is associated with proteinopathies such as 
neurodegenerative disorders, type 2 diabetes, cardiovascular disease, and cancer 
(Dobson, 2003; Hartl, Bracher, and Hayer-Hartl, 2011; Morimoto, 2008; Taylor, Hardy, 
and Fischbeck, 2002). 
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 How proteins achieve their native conformations has been the subject of 
research for many decades. The possible conformations a protein can adopt are 
astronomically large; thus, complex folding mechanisms are in place to promote the 
burial of hydrophobic residues and prevent aggregation (Hartl, Bracher, and Hayer-Hartl, 
2011; Zwanzig, Szabo, and Bagchi, 1992). Current theories suggest that competing 
reactions of protein folding and aggregation exist in the cell and form a funnel-shaped 
potential energy landscape (Figure 1.5) (Dobson, 2003; Hartl, Bracher, and Hayer-Hartl, 
2011; Kim, Hipp, et al, 2013). This theory postulates that there are few lower-energy, 
native-like conformations that a protein can have and that a protein travels on a downhill 
path toward a conformation of lowest energy (Dill, and MacCallum, 2012). As proteins 
move toward the native state, they form intramolecular contacts that create kinetically 
trapped intermediate conformations leading to free energy barriers that need to be 
overcome to reach the more favorable, low energy state. If many proteins are folding 
simultaneously in the same compartment, intermolecular contacts may form leading to 
the formation of amorphous aggregates, oligomers, or amyloid fibrils. Often times, the 
aggregated or fibrillar state may be most energetically favorable, though their formation 
is largely restricted in vivo. However, they may persist during times of stress or protein 
quality control failure (Dobson, 2003; Hartl, Bracher, and Hayer-Hartl, 2011).  
 Due to the complexity and significance of protein folding, the cell contains an 
elaborate protein quality control system to achieve proteostasis and maintain cellular 
health. Protein quality control is executed using an extensive network of proteins, the 
majority of which are molecular chaperones (Powers, Morimoto, et al, 2009). Although, 
the amino acid sequence is sufficient to confer three-dimensional structure to a protein,  
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Figure 1.5. Energy landscape of protein folding.  
Competing reactions between protein folding and aggregation naturally occur while a 
protein reaches its native structure. As proteins travel toward their native conformation, 
they form kinetically trapped intermediates that need to traverse energy barriers to reach 
their thermodynamically favorable conformation; steps made more efficient by molecular 
chaperones. Aggregates may form when inappropriate intermolecular contacts form 
during simultaneous folding of many proteins in the same compartments. In vivo, the 
formation of these structures is generally restrained by molecular chaperones. 
Reproduced with permission (Hartl, Bracher, and Hayer-Hartl, 2011). 
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many proteins require molecular chaperones to reach their native state efficiently 
(Anfinsen, 1973; Hartl, 1996). A molecular chaperone is defined as a protein that 
interacts with and helps another protein acquire its functionally active state without being 
present in its final structure (Hartl, 1996).  To achieve proteostasis, molecular 
chaperones can promote the refolding of an aberrantly folded protein, send a misfolded 
protein for degradation, or sequester the protein to specialized quality control 
compartments (Figure 1.6) (Chen, Retzlaff, et al, 2011). For the purposes of this 
dissertation, I will focus on molecular chaperones and their folding activities.  
Molecular chaperones interact with unfolded or partially folded protein subunits, 
for example, nascent chains emerging from the ribosome, where they participate in co-
translational folding (Frydman, Erdjument-Bromage, et al, 1999; Hartl, and Hayer-Hartl, 
2002; Netzer, and Hartl, 1997). The expression of molecular chaperones is often 
increased by cellular stress. Molecular chaperones can also stabilize non-native 
conformations and facilitate correct folding of protein subunits via coupling of ATP 
binding/hydrolysis to the folding process. In vivo, molecular chaperones strongly restrict 
the formation of aggregates and increase the overall efficiency of the protein folding 
process by reducing the probability of competing reactions, especially aggregation 
(Figure 1.5) (Dobson, 2003; Hartl, Bracher, and Hayer-Hartl, 2011).  
One of the major classes of chaperones in the cells are the heat shock proteins 
(Hsps), so named because their expression is often upregulated upon the induction of 
cellular stress including heat shock, oxidative damage, and hypoxia, among others 
(Santoro, 2000; Whitley, Goldberg, and Jordan, 1999). The Hsps are named according 
to their molecular weight (in kDa): Hsp100, Hsp90, Hsp70, Hsp60, Hsp40, and the small 
Hsps (sHsps). The Hsps are involved in a multitude of protein quality control activities  
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Figure 1.6. Chaperones and the proteostasis network.  
The proteostasis network encompasses a large network of proteins, the majority of 
which are molecular chaperones. The chaperones are necessary to fold newly 
synthesized proteins, refold misfolded proteins, prevent protein aggregation, promote 
disaggregation, and send misfolded proteins for degradation via the proteasome or 
autophagy. Reproduced with permission (Hartl, Bracher, and Hayer-Hartl, 2011). 
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including de novo protein folding, refolding of stress-denatured proteins, signal 
transduction, and proteolytic degradation. The chaperones mainly involved in protein 
folding and refolding are the Hsp40s, Hsp70s, Hsp90s, Hsp100s and the Hsp60s, which 
are also known as chaperonins (Hartl, 1996; Hartl, Bracher, and Hayer-Hartl, 2011; Kim, 
Hipp, et al, 2013).  
 The function of the Hsp70 family of chaperones in protein folding can be 
described as the prevention of aggregation, the promotion of folding to the native state, 
and the solubilization and refolding of misfolded proteins (Mayer, and Bukau, 2005).  
The Hsp70 proteins have three main structural domains. The first is an N-terminal 
ATPase domain, which binds ATP and hydrolyzes it to ADP, a process catalyzed via 
association with Hsp40. The second is a substrate-binding domain that has affinity for 
the exposed hydrophobic regions on peptide segments. By binding to the hydrophobic 
patches on substrate molecules, Hsp70 and Hsp40 can prevent aggregation by blocking 
inappropriate interactions between non-native structures. Interestingly, the surface 
potential surrounding the substrate binding domain is negatively charged, which explains 
the contribution of positive charges in peptides for the affinity of Hsp70. Finally, the C-
terminal portion is rich in α-helical structures, acting as lid for the substrate binding 
domain (Mayer, and Bukau, 2005). Hsp70 and Hsp40 can also assist non-native folding 
intermediates to fold into their native structures; however, the mechanism as to how this 
occurs is unclear (Mayer, and Bukau, 2005). Hsp70 also works in cooperation with the 
Hsp60 (chaperonin) class of chaperones to mediate protein folding. Chaperonins are 
large ring-like complexes that enclose substrates in their central cavity for folding 
(Horwich, Fenton, et al, 2007). Hsp70 and the chaperonins work together to aid nascent 
polypeptides in reaching their native structure; Hsp70 interacts with nascent 
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polypeptides as they emerge from the ribosome while the chaperonins act downstream 
to trap those substrates that escape the folding activity of Hsp70 (Frydman, 
Nimmesgern, et al, 1994; Langer, Lu, et al, 1992). Recently, an intriguing property of 
Hsp70 has emerged whereby, in an ATP-dependent manner, Hsp70 converts misfolded 
substrates into unfolded intermediates, which are then able to refold to their native state 
upon release from Hsp70. These results challenge the theory that Hsp70 chaperones 
are able to fold proteins; rather, they point toward an unfolding function prior to 
chaperone-independent refolding (Sharma, De los Rios, et al, 2010).  
 Despite the wealth of information regarding protein folding and misfolding, there 
is little known about how protein aggregation is reversed in the cell. It is known that the 
heat shock proteins can prevent aggregation, but very few possess disaggregation 
activity. The chaperonin, specifically GroEL-GroES in bacteria, and the Hsp70/40 
systems have demonstrated in vitro disaggregation and reactivation ability in very 
specific cases using particular substrates: RNA polymerase (Skowyra, Georgopoulos, 
and Zylicz, 1990; Ziemienowicz, Skowyra, et al, 1993), malate dehydrogenase (Veinger, 
Diamant, et al, 1998) and glucose-6-phosphate dehydrogenase (Diamant, Ben-Zvi, et al, 
2000). Most bacteria and eukaryotes including protozoa, fungi, and plants contain 
homologs of the AAA+ ATPase, Hsp104, a member of the Hsp100 class of chaperones. 
Hsp104 from yeast, in concert with Hsp70/40, can disaggregate and reactivate 
chemically denatured proteins in vitro (Glover, and Lindquist, 1998; Goloubinoff, Mogk, 
et al, 1999). Hsp104 also confers thermotolerance to yeast cells; a property related to its 
ability to rescue misfolded or aggregated proteins (Sanchez, Taulien, et al, 1992). 
Hsp104 can cooperate with mammalian Hsp70/40 for disaggregation indicating that 
there is no species barrier between yeast Hsp104 and mammalian chaperones (Shorter, 
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2011). Strikingly, there is no metazoan homolog for Hsp104. Thus, it remains unclear if 
mammalian cells contain disaggregation abilities.  
Recent studies have tried to determine if mammalian cells contain potent 
disaggregation activity and if this activity can be attributed to a single protein. Valosin-
containing protein (VCP or p97), a member of the AAA+ ATPase family, has emerged as 
an attractive candidate. VCP is able to prevent the aggregation of denatured luciferase 
both in vivo and in vitro and it can also assist in the suppression and clearance of protein 
aggregates; however, its activity has not been clearly established (Kobayashi, Manno, 
and Kakizuka, 2007; Song, Wang, and Li, 2007). Recently, an Hsp70-related protein, 
Hsp110 has been shown to cooperate with Hsp70/40 in the mammalian cytosol to 
disaggregate and reactivate aggregated GFP and luciferase (Mattoo, Sharma, et al, 
2013; Shorter, 2011). These results established that Hsp110, Hsp70, and Hsp40 
constitute an ATP-dependent disaggregase machinery that is active in the mammalian 
cytosol and can act upon disordered, amorphous aggregates. Further, Hsp110, Hsp70, 
and Hsp40 can enhance the activity of Hsp104 in the disaggregation of amyloid fibers 
(Shorter, 2011).  
All together, this evidence indicates that metazoan cells do possess 
disaggregation activity. Elucidation of the mediating factors in protein refolding and 
disaggregation would help in identifying new therapeutics for diseases caused by protein 
misfolding. Indeed, it has been shown that Hsp104, despite being a yeast protein, can 
be therapeutically efficacious in metazoan disorders such as Alzheimer’s and 
Parkinson’s disease, albeit in generally in vitro settings (Vashist, Cushman, and Shorter, 
2010), underscoring the potential of molecular chaperones in ameliorating disease. In 
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chapter three, I examine the activity of Daxx in protein folding, potentially establishing it 
as a novel molecular chaperone.   
The Mammalian Cell Cycle 
Cell cycle regulation is crucial to the survival of the cell not only because it 
controls the growth of the cell, but also because it allows the cell time to detect and 
repair genetic damage. The mammalian cell cycle consists of four distinct phases—G1 
(gap phase), S (synthesis), G2 (gap phase), and M (mitosis) phases (Figure 1.7). Cells 
that have temporarily or reversibly stopped dividing are said to enter a state of 
quiescence known as G0. G1, S, and G2 are collectively known as interphase, where 
the cell spends the majority of its time preparing for division via the acquisition of 
nutrients and replication of its DNA (Vermeulen, Van Bockstaele, and Berneman, 2003). 
The cell cycle is controlled by a number of checkpoints that facilitate the progression of 
the cell through the cycle ensuring that the cell is free of any defects in DNA synthesis or 
chromosome segregation (Malumbres, and Barbacid, 2009). The first checkpoint the cell 
encounters is the restriction (R) point. Once they pass this point, cells are able to 
proliferate without extracellular mitogenic stimuli (Pardee, 1974). The cell cycle is highly 
influenced by the proper expression of cyclins and their associated cyclin-dependent 
kinases (Cdks), which form specific complexes at each stage of the cell cycle to facilitate 
proper progression (Figure 1.7).  
 During G0 and G1 phase, the cell cycle is influenced by external mitogenic 
signals. Once activated by these extracellular signals, the D-type cyclins pair with their 
catalytic partners, Cdk4 and Cdk6, to promote progression through G1 phase (Sherr, 
and Roberts, 2004). The cyclin D-Cdk complexes work to promote cell division via the 
inactivation of two classes of cell cycle inhibitors: negative regulators of S-phase gene  
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Figure 1.7. Schematic depicting the mammalian cell cycle.  
The cell cycle is divided into four phases: G1 (first gap phase), S (DNA synthesis 
phase), G2 (second gap phase), and M (mitosis). Cyclin-Cdk complexes regulate the 
various stages of the cell cycle. G0 is a period of quiescence during which the cells have 
temporarily or reversibly stopped dividing. The R denotes the restriction point at which 
stage the cells do not require mitogenic signals to continue signaling.  
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expression and the Cip/Kip family of proteins (Sherr, and Roberts, 2004). Cyclin D-Cdk 
complexes are known to phosphorylate and functionally inactivate the retinoblastoma 
protein (pRb) and the pRb-related proteins, p107 and p130 (Harbour, Luo, et al, 1999). 
Inhibition of pRb leads to derepression of the E2F family of transcription factors, allowing 
transcription of a variety of proteins necessary for DNA metabolism and replication, 
ultimately allowing for progression into S phase. Additionally, the cyclin D-Cdk 
complexes are able to sequester p27 (Kip1) and p21 (Cip1) away from cyclin E-Cdk2 
and cyclin A-Cdk2, relieving Cdk2 inhibition by p27 and p21 (Sherr, and Roberts, 1995; 
Toyoshima, and Hunter, 1994). If mitogenic signals are withdrawn, the cyclin D-Cdk 
complexes dissociate, allowing for mobilization of p27 bound to those complexes. Once 
freed from the complex, p27 is able to inhibit cyclin E-Cdk2 and promote exit from the 
cell cycle (Poon, Toyoshima, and Hunter, 1995).  
 The activation of E2F by the cyclin D-Cdk complexes during G1 leads to the 
transcription of cyclin E, allowing for the formation of cyclin E-Cdk2 complexes. This 
complex also phosphorylates pRb, allowing for further activation of E2F activity (Ohtani, 
DeGregori, and Nevins, 1995). pRb remains phosphorylated throughout the S, G2, and 
M phases and becomes dephosphorylated during the transition from M to G1 by PP1 
(Ludlow, Glendening, et al, 1993; Nelson, Krucher, and Ludlow, 1997). The cyclin E-
Cdk2 complex is at maximal activity at the transition between G1 and S phase and its 
activity significantly decreases at the beginning of S phase due to proteolytic 
degradation of cyclin E (Clurman, Sheaff, et al, 1996). Cyclin E-Cdk2 is responsible for 
the initiation of DNA synthesis and proper completion of S phase. As DNA replication 
continues, cyclin E levels decrease and the level of the mitotic cyclins (cyclins A and B) 
begins to increase (Sherr, and Roberts, 2004). Cyclin A-Cdk2 activity is first detected in 
late G1 phase and steadily increases as the cells begin to replicate their DNA, after 
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which cyclin A is degraded before metaphase (Fung, and Poon, 2005). During S phase, 
the cyclin A-Cdk2 complex can phosphorylate substrates that start DNA replication from 
preassembled replication initiation complexes (Krude, Jackman, et al, 1997). After 
proteolytic degradation of cyclin A, cyclin B-Cdk1 complexes begin the transition into M 
phase (Mitra, and Enders, 2004). Activation of cyclin B-Cdk1 triggers its rapid 
accumulation in the nucleus and its levels continue to rise until the beginning of mitosis, 
after which they fall due to degradation of cyclin B. Activation of cyclin B-Cdk1 results in 
the breakdown of the nuclear envelope and the initiation of prophase (Hagting, Jackman, 
et al, 1999).  
  It is clear that the cell cycle is a carefully controlled process that utilizes cyclin-
Cdk complexes for proper progression. However, this prevailing dogma has been 
challenged suggesting that not all these cyclins and Cdks are required for proper cellular 
proliferation. Genetic studies in mice have shown that mouse strains lacking each of the 
D-cyclins separately are mostly viable and display very narrow and restricted 
developmental abnormalities (Ciemerych, Kenney, et al, 2002; Fantl, Stamp, et al, 1995; 
Sicinska, Aifantis, et al, 2003; Sicinski, Donaher, et al, 1995). Cyclin D1-deficient mice 
are generally smaller in size and have severe hypoplastic retinas and pregnancy-
insensitive mammary glands. Deletion of cyclin D2 in mice leads to female sterility due to 
the inability of ovarian granulosa cells to proliferate normally in response to follicle-
stimulating hormone (FSH). Male mice are still fertile but display hypoplastic testes 
(Sicinski, Donaher, et al, 1996). Finally, mice deficient in cyclin D3 have lymphoid 
abnormalities but are still viable (Sicinska, Aifantis, et al, 2003). Mice lacking all three 
cyclins appear normal until E13.5; however, they eventually die by E17.5 due to severe 
anemia and cardiac abnormalities. Interestingly, fibroblasts derived from these embryos 
were sustainable in culture albeit requiring higher mitogen concentrations to grow 
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(Kozar, Ciemerych, et al, 2004). 
 The necessity of the Cdks has also been studied and knockout mice lacking the 
various Cdks have been generated. Cdk1 -/- mice displayed arrested embryonic 
development at the blastocyst stage and MEFs lacking Cdk1 were unable to proliferate 
as the cells underwent premature senescence, suggesting that Cdk1 is essential for 
proliferation (Diril, Ratnacaram, et al, 2012). Conversely, deletion of Cdk2 was shown to 
have no effect on mitosis in mice, but was important for the completion of prophase I 
during meiosis in both male and female germ cells (Berthet, Aleem, et al, 2003; Ortega, 
Prieto, et al, 2003). Mice deficient in Cdk4 and Cdk6 have also been generated; they are 
viable and show very narrow, tissue-specific defects (Kozar, and Sicinski, 2005). When 
only Cdk4 is deleted, the mice have a reduced body size, are sterile, and become 
diabetic due to a reduced number of pancreatic β cells (Martin, Hunt, et al, 2003; Rane, 
Dubus, et al, 1999). Cdk6 -/- mice display defective hematopoiesis and lower cellularity 
in the thymus and spleen. The loss of Cdk6 also leads to delayed G1 progression in 
lymphocytes. Further observations suggest that Cdk6 is more essential for the 
expansion of differentiated populations rather than for proliferation of hematopoietic 
precursors (Malumbres, Sotillo, et al, 2004). The same study characterized double 
knockout Cdk4;Cdk6 -/- mice and demonstrated that embryos died beginning at E14.5 
until the end of gestation due to severe anemia and major defects in multiple 
hematopoietic lineages. Many tissues still had normal proliferation rates and fibroblasts 
cultured from the double knockout embryos were able to cycle relatively normally.  
 The importance of the cell cycle proteins is underscored by the fact that their 
deregulation has been observed in various types of cancer. (Vermeulen, Van 
Bockstaele, and Berneman, 2003). In fact, overexpression of the D and E cyclins and 
Cdk4 are commonly observed in human tumors (Akli, and Keyomarsi, 2003; An, 
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Beckmann, et al, 1999; Diehl, 2002; Donnellan, and Chetty, 1999; Yu, Sicinska, et al, 
2006). It is possible that pharmacological disruption of these complexes may yield 
therapeutic efficacy for specific cancers. Yet, ambiguity exists regarding the necessity of 
these different proteins in cell cycle progression. Therefore, determining the cell-type 
specificity and regulation of these canonical cell cycle proteins is essential for 
understanding cellular proliferation. In chapter four, I discuss a novel function for Daxx 
as a potential regulator of the cell cycle associated protein, Cdk6.  
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CHAPTER 2:  THE ROLE OF DAXX IN p53 REGULATION 
INTRODUCTION 
 Tumor suppressors are necessary to prevent the proliferation of cells carrying 
cancer-causing alterations. These alterations can include the activation of an oncogene 
or DNA damage. The major responder to these cellular stresses is the tumor suppressor 
p53. Upon activation, p53 can induce apoptosis, cell cycle arrest, or senescence, 
amongst many other activities (Vogelstein, Lane, and Levine, 2000; Vousden, and 
Prives, 2009). Due to its potent anti-proliferative activity, p53 is highly constrained by the 
E3 ubiquitin ligase, Mdm2 (Haupt, Maya, et al, 1997; Kubbutat, Jones, and Vousden, 
1997). In unstressed cells, p53 levels are maintained at a low level via ubiquitination by 
Mdm2; however, upon the induction of various stresses, Mdm2 stabilization is impaired 
and p53 levels are able to rise (Vogelstein, Lane, and Levine, 2000). Upon DNA 
damage, ATM is activated, leading to phosphorylation of p53 at Ser15 and at Ser20 by 
Chk2, a downstream kinase of ATM. These phosphorylation events cause stabilization 
of p53, partially via disruption of the p53-Mdm2 complex (Banin, Moyal, et al, 1998; 
Canman, Lim, et al, 1998; Shieh, Ahn, et al, 2000). Subsequent studies demonstrated 
that mutation of the phosphorylation sites in murine p53 do not robustly reduce p53 
stabilization after DNA damage, indicating that other events are necessary for sustained 
p53 activation (Chao, Hergenhahn, et al, 2003; MacPherson, Kim, et al, 2004; Sluss, 
Armata, et al, 2004).  
 Our lab has previously shown that Daxx is a critical regulator of Mdm2 via the 
simultaneous association of Daxx with Hausp, a deubiquitinase, and Mdm2 in 
unstressed cells (Tang, Qu, et al, 2006). Thus, Daxx bridges Hausp to Mdm2, which 
deubiquitinates Mdm2 allowing for its stability and consequential p53 inactivation. 
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Induction of DNA damage leads to disruption of the Daxx-Mdm2-Hausp complex in an 
ATM-dependent manner allowing for p53 activation (Tang, Qu, et al, 2006). It is known 
that ATM phosphorylates Ser395 on Mdm2 and that this event interferes with the 
inhibitory effect of Mdm2 on p53 (Maya, Balass, et al, 2001). More recently it has been 
shown that ATM phosphorylates multiple sites in the C-terminus of Mdm2 upon DNA 
damage. These sites act redundantly to inhibit p53 degradation and stabilize p53 
(Cheng, Chen, et al, 2009). When a phospho-mimic mutant of Mdm2 (S395D) was used 
to test its ability to associate with Daxx, it exhibited similar binding to Daxx as compared 
to wild-type Mdm2. This suggests that the Daxx-Mdm2-Hausp complex is potentially 
being regulated by additional phosphorylation events mediated by ATM. In the present 
study, we hypothesize that Daxx is an ATM target and that Daxx phosphorylation is 
important for its interaction with Mdm2 and consequential p53 activation. This study was 
recently published and demonstrated that Daxx is phosphorylated at Ser564 in response 
to DNA damage in an ATM-dependent manner (Tang, Agrawal, et al, 2013). Dr. Jun 
Tang identified the phosphorylation site on Daxx and raised the phospho-specific 
antibody to the aforementioned site. She also determined the ATM-dependence of this 
site in vivo. I performed the in vitro kinase assay demonstrating that ATM directly 
phosphorylates Daxx. I also executed subsequent analyses of Daxx phosphorylation 
regarding Mdm2 stability and p53 activation.  
RESULTS 
Daxx is phosphorylated at Ser564 by ATM in response to DNA damage 
 To determine if ATM phosphorylates Daxx during DNA damage, an antibody that 
recognizes the ATM substrate consensus sequence X-Ser/Thr-Gln (where X is a 
hydrophobic residue) was used to detect Daxx phosphorylation in human lung 
32 
 
carcinoma (H1299) cells. The cells were transfected with Flag-Daxx and then treated 
with the genotoxic drug etoposide (ETP). Western analysis indicated that Daxx is 
phosphorylated soon after DNA damage induction and that this phosphorylation persists 
for at least eight hours (Figure 2.1). To map the phosphorylation site, residues from the 
N-terminus of Daxx were progressively deleted and these Daxx truncation mutants were 
transfected into H1299 cells treated with or without etoposide (Figure 2.2, A and B). 
Daxx phosphorylation was not detected for amino acids 570-740 but was detected in the 
other fragments, suggesting that the phosphorylation site resides within residues 340-
570 of Daxx (Figure 2.2B). Analysis of this region revealed two potential ATM consensus 
sites: MAS424QG and PVS564QL. Both Ser424 and Ser564 were mutated to S424A and 
S564A and expressed in H1299 cells treated with or without etoposide. The S564A 
mutation, but not the S424A mutation, abolished Daxx phosphorylation upon treatment 
with etoposide indicating that S564 is the major ATM-targeted phosphorylation site on 
Daxx upon DNA damage (Figure 2.2C, lane 4 vs. 2 and 6). The Daxx Ser564 ATM 
consensus site is evolutionarily conserved across mammalian species, but not in fish or 
flies (Figure 2.3).  
Phosphorylation of endogenous Daxx upon DNA damage 
 
 An antibody specific for the phosphorylated Ser564 residue on Daxx was made 
to confirm the modification of this site upon DNA damage (pS564-Daxx). This antibody 
detected phosphorylation of Daxx upon DNA damage in human osteosarcoma (U2OS) 
cells (Figure 2.4A, lane 2) and this signal was diminished when Daxx was knocked down 
using siRNA (Figure 2.4A, lane 4 vs. 2), underscoring the specificity of this antibody 
toward Daxx. To confirm that this antibody was recognizing phosphorylated Ser564, 
either wild-type, S564A, or S424A Daxx was expressed in H1299 cells and challenged  
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Figure 2.1. Daxx is phosphorylated upon DNA damage.  
p53-deficient H1299 cells were transiently transfected with Flag-Daxx. 24 h later, the 
cells were treated with 10 µM etoposide (ETP) for the indicated durations. Cells were 
lysed and Flag-Daxx was immunoprecipitated with anti-Flag mAb beads and analyzed 
by western blot with antibodies against Daxx or phosphorylated ATM substrate 
consensus site (pS/T-Q). Performed by Dr. Jun Tang. 
  
34 
 
 
 
 
Figure 2.2. Daxx is phosphorylated at Ser564 upon DNA damage.  
(A) Schematic representation of full length Daxx and its N-terminal deletion mutants. 
PAH, paired amphipathic helical domains. D/E, acid-rich region. SPT, Ser/Pro/Thr-rich 
domain. The amino acids in full length Daxx and in the N-terminus of each deletion 
mutant, and phosphorylation status (Pi) of these mutants are indicated. (B) H1299 cells 
expressing full-length (FL) Daxx and each of the deletion mutants were treated with 10 
µM ETP for 1 h. Phosphorylation of these proteins was analyzed using Daxx and ATM 
substrate consensus site (pS/T-Q) antibodies. Exogenous Daxx phosphorylation existing 
before DNA damage was observed in some experiments, but not others. (C) 
Phosphorylation of Daxx, Daxx S424A, and Daxx S564A upon DNA damage was 
analyzed as in (B). Performed by Dr. Jun Tang. 
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Figure 2.3. Ser564 of Daxx is evolutionarily conserved.  
Alignment of the human Daxx (gi|48146287) sequence around Ser564 with the 
corresponding Daxx sequences from Bos taurus (gi|296474559), Canis lupis familiaris 
(gi|55956960), Mus musculus (gi|2253707), Rattus norvegicus (gi|18148939), Salmo 
salar (gi|148362139), and Drosophila melanogaster (gi|54144924). Alignment was run 
using Clustal W2 (Goujon, McWilliam, et al, 2010; Larkin, Blackshields, et al, 2007). 
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Figure 2.4. Phosphorylation of endogenous Daxx upon DNA damage.  
(A) U2OS cells were transfected with control or Daxx siRNA and treated with 10 µM ETP 
for 1 h. Cell lysates were analyzed by western blot using the phospho-specific Daxx 
antibody, pS564-Daxx. (B) Western blot analysis of H1299 cells transfected with wild-
type (WT) Daxx, Daxx S564A, or Daxx S424A and treated with ETP for 1 h using pS564-
Daxx. (C) Phosphorylation of endogenous Daxx in multiple cell lines treated with and 
without etoposide for 1 h. Cell lysates were analyzed using antibodies against pS564-
Daxx, Daxx, p53, and actin. Saos-2 (human osteosarcoma, p53 null); HT1080 (human 
fibrosarcoma); HeLa (human cervix adenocarcinoma, p53 null); 293T (human embryonic 
kidney); IMR90 (primary human lung fibroblast). Performed by Dr. Jun Tang. 
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with etoposide. The phosphorylated Daxx band intensity was greatly decreased when 
Daxx S564A was expressed compared to wild-type or S424A Daxx (Figure 2.4B, lane 4  
vs. lanes 2 and 6), further confirming the specificity of this antibody for phosphorylated 
Ser564. When this antibody was applied to cell lysates from a variety of cancer and 
primary cell lines, it was able to recognize DNA damage-induced Daxx phosphorylation 
in all cases, indicating the generality of this effect and its independence of p53 status 
(Figure 2.4C).  
Daxx is phosphorylated by ATM in vivo and in vitro 
 
 To confirm the ATM-dependence of this phosphorylation event, in vivo and in 
vitro experiments were performed. First, H1299 cells were treated with ATM siRNA and 
etoposide. The lysates were analyzed with the phospho-specific antibody against 
Ser564 of Daxx, which showed that endogenous Daxx phosphorylation was diminished 
in ATM-depleted cells (Figure 2.5A, lane 4 vs. 2). To determine whether ATM directly 
phosphorylates Daxx at Ser564, we performed an in vitro kinase assay with various 
purified recombinant ATM and Daxx proteins in the presence of γ-32P-ATP. Daxx was 
then analyzed by autoradiography, as well as by western blot using the anti-pS564-Daxx 
antibody. Daxx was phosphorylated in vitro by wild-type ATM, but not by a kinase-dead 
(KD) ATM mutant (Figure 2.5B, lanes 1 vs. 2). The small amount of pS564-Daxx signal 
in the reaction containing ATM KD (lane 2) was likely due to phosphorylation that pre-
existed on the Daxx protein purified from HEK293 cells, because minimal 32P 
incorporation of Daxx was detected in this reaction. Compared to Daxx, ATM-mediated 
phosphorylation of Daxx S564A was weakly detected by 32P incorporation (lane 3), but 
not by anti-pS564 antibody (lane 4). This weak phosphorylation likely occurred on an 
amino acid residue(s) distinct from S564. Together, these data indicate that ATM can  
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Figure 2.5. Daxx is phosphorylated by ATM in vivo and in vitro.  
(A) H1299 cells treated with ATM siRNA or control siRNA were subject to DNA damage 
and analyzed for phosphorylation using pS564-Daxx antibody. Performed by Dr. Jun 
Tang. (B) In vitro kinase assay depicting Ser564 phosphorylation by ATM. Top two 
panels: phosphorylated Daxx was detected by autoradiography (32P-Daxx) and western 
blot (pS564-Daxx). Bottom two panels: input of ATM and Daxx proteins were analyzed 
by western blot and Coomassie staining, respectively.  
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phosphorylate Daxx directly and mainly at Ser564. 
Phosphorylation of Daxx at Ser564 regulates its interaction with Mdm2 
 
 Next, we sought to determine if phosphorylation of Daxx by ATM affected its 
interaction with Mdm2 and if this would have downstream consequences on the 
activation of p53. To determine if the binding of Daxx and Mdm2 was affected, we 
performed an immunoprecipitation where HA-Daxx or HA-Daxx S564A was co-
transfected with Flag-Mdm2 in H1299 cells and Mdm2 was pulled down using anti-Flag 
beads. The co-immunoprecipitation assay showed that wild-type Daxx and Mdm2 readily 
dissociated from each other upon etoposide treatment; however, Daxx S564A continued 
to associate with Mdm2 during etoposide treatment, suggesting that the lack of Ser564 
phosphorylation on Daxx enhances its interaction with Mdm2 (Figure 2.6A, lanes 6-8 vs. 
3-5).  
 It is known that ATM can phosphorylate Mdm2 at Ser395 upon DNA damage 
(Maya, Balass, et al, 2001). We evaluated how the binding of wild-type and S564A Daxx 
would be affected with a phospho-mimic mutant of Mdm2 (S395D). Compared to wild-
type Daxx, Daxx S564A was able to bind more strongly to Mdm2 S395D suggesting that 
a lack of phosphorylation at Ser564 on Daxx increases its ability to bind to 
phosphorylated Mdm2 (Figure 2.6B, lanes 3 vs. 2). Furthermore, a previous study 
reported that Daxx could be phosphorylated at Ser712 by the ATM/ATR signaling 
network (Matsuoka, Ballif, et al, 2007). To examine whether this phosphorylation site 
was involved in the Mdm2 interaction, a mutant form of Daxx was created (S712A) along 
with a double mutant where both the Ser564 and Ser712 were mutated to alanine (2SA). 
Daxx S712A displayed a similar binding affinity for Mdm2 S395D as wild-type Daxx 
(Figure 2.6B, lanes 4 vs. 2). Additionally, Daxx 2SA and Daxx S564A had  
40 
 
 
 
 
 
 
Figure 2.6. Phosphorylation of Daxx at Ser564 regulates its interaction with Mdm2.  
(A) H1299 cells were transfected with either HA-Daxx or HA-Daxx S564A alone, or 
together with Flag-Mdm2. Cells were treated with MG132 (20 µM) for 4 h and ETP (20 
µM) for the indicated times. Cell lysates were incubated with anti-Flag mAb beads. Input 
and immunoprecipitated proteins were analyzed by western blot using HA-HRP antibody 
for Daxx and Flag-HRP antibody for Mdm2. (B) HA-Mdm2 S395D was transfected alone 
and together with the indicated Flag-Daxx plasmids into p53-/- Mdm2-/- MEFs (mouse 
embryonic fibroblasts). Cell lysates were incubated with anti-Flag mAb beads. The input 
lysates and immunoprecipitated proteins were analyzed by western blotting. 
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indistinguishable interactions with Mdm2 S395D (Figure 2.6B, lanes 5 vs. 3). These 
results indicate that phosphorylation at Ser564 is the main event that disrupts the 
interaction of Daxx with phosphorylated Mdm2.  
 To determine if Daxx phosphorylation mediated the stability of Mdm2, we 
performed half-life analyses using the protein translation inhibitor cycloheximide. First, 
we expressed Mdm2 alone or with wild-type or Daxx S564A in H1299 cells. Wild-type 
Daxx was able to increase the protein expression and half-life of Mdm2 compared to 
when Mdm2 was expressed alone (Figure 2.7A, lanes 5-8 vs. 1-4) and Daxx S564A 
further enhanced the stability and half-life of Mdm2 (Figure 2.7A, lanes 9-12 vs. 5-8). To 
determine the effect of Daxx S564A on endogenous Mdm2, U2OS stable cell lines were 
established via retroviral transduction to express wild-type Daxx or Daxx S564A. The 
cells lines stably expressing Daxx S564A showed a greater ability to stabilize Mdm2 and 
increase its half-life, when compared to wild-type Daxx (Figure 2.7B, lanes 9-12 vs. 5-8). 
Finally, we tested whether this increase in half-life also occurred upon DNA damage. We 
expressed Mdm2 together with either Daxx or Daxx S564A. Etoposide was used to 
induce DNA damage after which cycloheximide was administered to the cells. Mdm2 
stability was enhanced in the presence of Daxx, as expected (Figure 2.7C, lanes 5-8 vs. 
1-4). Mdm2 stability was further enhanced when Daxx S564A was co-expressed, even 
though Daxx S564A expressed at a much lower level than wild-type Daxx (Figure 2.7C, 
lanes 9-12 vs. 5-8).  
 Our previous study indicated that Daxx is able to stabilize Mdm2 via association 
with Hausp (Tang, Qu, et al, 2006). To confirm that Daxx S564A-mediated stabilization 
of Mdm2 was also dependent upon Hausp, we treated U2OS cells with either Hausp or 
control siRNA and expressed increasing amounts of Daxx S564A. Endogenous Mdm2 
stability is enhanced in the presence of Daxx S564A (Figure 2.8, lanes 2-4 vs. 1), but the  
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Figure 2.7. Phosphorylation of Daxx at Ser564 regulates the half-life of Mdm2.  
(A) H1299 cells were transfected with HA-Mdm2 alone or with Flag-Daxx or Flag-Daxx 
S564A. Cells were treated with CHX (50 µg/ml) for indicated time and subjected to 
western blot analysis. Tubulin and GFP are shown as controls for sample loading and 
transfection efficiency, respectively. (B) Daxx S564A can prolong the half-life of 
endogenous Mdm2. U2OS cells stably expressing Flag-Daxx or Flag-Daxx S564A were 
treated with CHX (20 µg/mL) for the indicated times. Samples were analyzed using 
Mdm2, Daxx, and tubulin antibodies. (C) Daxx S564A can prolong the half-life of Mdm2 
upon DNA damage. Flag-Mdm2 was transfected alone or together with the indicated HA-
Daxx plasmids into p53-/- Mdm2-/- MEFs. Cells were treated with ETP (20 µM) for 1 h 
prior to cycloheximide (CHX, 50 µg/ml) treatment for indicated times. GFP and actin are 
shown as controls for transfection efficiency and sample loading, respectively. Asterisk 
indicates non-specific band. 
* 
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Figure 2.8. The effect of Daxx S564A on Mdm2 is dependent upon Hausp.  
Increasing amounts of Flag-Daxx S564A were transfected into U2OS cells treated with 
either control or Hausp siRNA and analyzed by western blot. Actin and GFP are shown 
as controls for sample loading and transfection efficiency, respectively.  
 
 
 
 
 
 
44 
 
effect is greatly diminished in Hausp-silenced cells (Figure 2.8, lanes 5-8 vs. 1-4).  
ATM-mediated phosphorylation of Daxx leads to p53 activation 
 
 We next examined if Daxx phosphorylation had consequences for p53 activation. 
Using human breast adenocarcinoma (MCF-7) cells, we stably expressed wild-type or 
S564A Daxx and assessed p53 levels. When Daxx S564A was present, there was an 
impairment of p53 activation upon etoposide treatment, presumably via greater 
stabilization of Mdm2 as compared to wild-type Daxx (Figure 2.9). The functional 
consequence of lower p53 levels was analyzed by measuring the protein (Figure 2.9A) 
and mRNA levels (Figure 2.9B) of the major p53 transcriptional target, p21. In both 
instances, p21 induction was weakened in the presence of Daxx S564A. These results 
indicate that ATM-mediated phosphorylation of Daxx upon DNA damage leads to Mdm2 
instability and p53 activation.  
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Figure 2.9. ATM-mediated phosphorylation of Daxx at Ser564 leads to p53 
activation.  
MCF-7 (A, done by Dr. Jun Tang) and U2OS (B) cells stably expressing Flag-Daxx or 
Flag-Daxx S564A were treated with 10 µM ETP for 8 h. Protein (A) and mRNA (B) 
expression was analyzed by western blot and quantitative RT-PCR.  
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MATERIALS AND METHODS 
Antibodies and plasmids - Antibodies for the following proteins/epitopes were purchased 
from the indicated sources: actin (A2066), tubulin (T4026), and Flag (mouse monoclonal, 
M2, free (F3615) and conjugated to beads (A2220), and rabbit polyclonal (F7425)) 
(Sigma); ATM (Ab-3) and Mdm2 (Ab-1 and Ab-3) (Calbiochem); Daxx (M-112), p53 (DO-
1), (Santa Cruz Biotechnology); phosphorylated ATM/ATR consensus site (X-pSer/Thr-
Gln, where X is a hydrophobic residue) (#2851, Cell Signaling); GFP (JL-8, Clontech); 
Hausp/USP7 (A300, Bethyl Laboratories, Inc.); HA conjugated to horseradish 
peroxidase (Roche). Antibody specific to Phospho-Daxx Ser564 was made by Invitrogen 
using peptide PEELTLEEESPVpSQLFELEIEA. Plasmids encoding HA- or Flag-tagged  
Mdm2 and Daxx for transient transfection were made in pRK5, and plasmids encoding 
Flag-tagged Daxx for stable infection were made in the retroviral vector pBabe-puro. 
They were either previously described (Tang, Qu, et al, 2006), or generated for this 
study by PCR and confirmed by sequencing. ATM and ATM KD expression plasmids 
were kindly provided by Dr. M. B. Kastan.  
 
Cell Culture - All cells were obtained from the ATCC. H1299 cells were grown in RPMI-
40 media and all other cell lines in Dulbecco’s modified Eagle’s medium, supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin. For generating Daxx and 
control stable cell lines, retroviral constructs for Flag-Daxx and Flag-Daxx S564A, as 
well as the parental vector pBabe-puro, were separately transfected into either phoenix 
cells along with the retroviral packaging vector pCL-Ampho, or HEK293T cells along with 
pcgp (which encodes gag pol) and pHIT 456 (which encodes retroviral envelope). 48-72 
h after transfection, the retrovirus-containing medium was used to infect U2OS or MCF-7 
cells in the presence of 8 µg/mL polybrene. The infected cells were selected in the 
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presence of 2 µg/ml puromycin for 4-5 days. 
 
Immunoprecipitation and western blot - Transfections were carried out using 
Lipofectamine 2000 (for DNA) or RNAiMAX (for siRNA) (Invitrogen) according to the 
manufacturer’s instructions. siRNA sequence for Daxx was: CAG AAA CAT TAA TAA 
ACA ATA (Qiagen). siRNA sequence for Hausp was CCC AAA TTA TTC CGC CGG 
CAA A (Qiagen). 24 h after transfection, cells were lysed in IP lysis buffer (20 mM Tris-
HCl at pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 0.5% NP-40, 100 mM NaF, 1 mM 
PMSF, 1 mM DTT, 1X complete protease cocktail (Roche), and 10% glycerol). Samples 
were fractionated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). Flag-Daxx or Flag-Mdm2 was immunoprecipitated with anti-Flag mAb 
beads and analyzed by western blot with anti-Daxx antibody (1:5,000), anti-
phosphorylated ATM/ATR consensus site (pS/T-Q) antibody (1:500), anti-Flag antibody 
(mouse or rabbit, 1:5,000), or anti-HA antibody (1:5,000).  
 
Kinase Assay - Flag-tagged ATM wild-type (WT), ATM kinase dead (KD), Daxx, and 
Daxx S564A were separately expressed in 293T cells and purified using M2 beads as 
previously described (Cheng, Chen, et al, 2009; Tang, Wu, et al, 2004). Daxx or Daxx 
S564A was incubated with ATM or ATM KD at 30°C for 1 h in kinase buffer (50 mM 
HEPES at pH 7.5, 150 mM NaCl, 20 mM MnCl2, and 1% Triton X-100) containing 2 µM 
ATP and 10 µCi γ-32P-ATP. Samples were fractionated on a 7.5% SDS-PAGE gel and 
detected by autoradiography and western blot.  
 
Quantitative RT-PCR analysis - Total RNA was isolated from cells using TRIzol 
(Invitrogen). Reverse Transcription was performed using the First Strand cDNA 
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Synthesis Kit (Marligen Biosciences). A Taqman Gene Expression Assay (Applied 
Biosystems) with validated human p21 (Hs00355782_m1) and 18s rRNA (4333760F) 
primers/probe sets (Applied Biosystems) were used for qPCR and analyzed. 
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CHAPTER 3:  DAXX AS A NOVEL MOLECULAR CHAPERONE 
 
INTRODUCTION 
Protein aggregation in cells arises due to the accumulation of misfolded proteins 
and leads to proteinopathies that can cause neurodegenerative diseases, diabetes, and 
cancer (Aguzzi, and O'Connor, 2010; Dobson, 2006; Xu, Reumers, et al, 2011). To 
contend with errors in protein folding, the cell maintains a sophisticated protein 
homeostasis network consisting of molecular chaperones to prevent aggregation or 
promote degradation of misfolded proteins (Dobson, 2003). Proteostasis is achieved 
using an extensive network of proteins, predominantly mediated via molecular 
chaperones (Hartl, Bracher, and Hayer-Hartl, 2011; Kim, Hipp, et al, 2013).  
The Hsp70 class of molecular chaperones assists a wide range of folding 
processes including prevention of aggregation, promotion of folding to the native state, 
and solubilization of aggregated proteins (Mayer, and Bukau, 2005). Hsp70s work with 
the Hsp40 family of molecular chaperones to prevent aggregation through binding with 
hydrophobic patches on their substrate molecules, preventing inappropriate 
intermolecular associations, which could lead to aggregation (Mayer, and Bukau, 2005). 
Hsp70 chaperones can also promote the refolding of non-native proteins, yet the 
mechanism as to how this occurs is unclear. It is thought that via repetitive binding and 
release cycles of the substrate with Hsp70, the free concentration of the substrate is 
kept low to prevent aggregation and free molecules are allowed to fold to the native state 
(Mayer, and Bukau, 2005). Alternatively, Hsp70 may promote local unfolding of the 
protein through binding and release cycles, after which the protein can spontaneously 
fold into the native structure (Ben-Zvi, and Goloubinoff, 2001; Bukau, and Horwich, 
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1998; Slepenkov, and Witt, 2002). Hsp70 chaperones can also promote the 
solubilization of misfolded and aggregated proteins; however, this only occurs via 
association of Hsp70 with Hsp104, a member of the Hsp100 class of chaperones.  
Intriguingly, there is no metazoan homolog for Hsp104 and to date, identification 
of a mammalian protein capable of renaturing large protein aggregates has remained 
elusive. Hsp104, a homolog of the AAA+ ATPase family, exists in the vast majority of 
bacteria and eukaryotes, but not in metazoan species (Doyle, and Wickner, 2009; 
Shorter, 2008; Vashist, Cushman, and Shorter, 2010). Hsp104 is able to rescue 
chemically denatured proteins after they have formed higher molecular weight 
aggregates, in combination with Hsp70 and Hsp40 (Glover, and Lindquist, 1998). It is 
unclear if animal cells possess protein disaggregases, but a potent mammalian 
disaggregating system has been discovered using a cell-free system, whereby Hsp110, 
a divergent relative of Hsp70, synergizes with Hsp70 and Hsp40 to confer protein 
disaggregase activity to the mammalian cytosol (Shorter, 2011).  
Despite these discoveries, it is still unclear how Hsp70 promotes the refolding of 
non-native structures and how metazoan cells counteract large protein aggregates. We 
propose that Daxx may be a mediator of protein folding in mammalian cells for several 
reasons. First, Daxx has a diverse array of binding partners leading it to have seemingly 
disparate functions within in the cell (Salomoni, and Khelifi, 2006). This is similar to the 
Hsp70 proteins, in that they demonstrate broad substrate specificity shown through their 
ability to associate with the entire spectrum of heat-denatured proteins in E. coli (Mogk, 
Tomoyasu, et al, 1999). Second, Daxx contains an acid-rich region enriched in Glu and 
Asp acid residues between amino acids 414 and 505, constituting a polyanionic region. 
This region is reminiscent of the C-terminal portion of the smaller heat shock proteins, 
51 
 
without which their activity is diminished (Narberhaus, 2002). Additionally, polyanions 
such as nucleic acids and tubulin demonstrate in vitro chaperone activity (Guha, Manna, 
et al, 1998; Jones, Yazzie, and Middaugh, 2004; Rentzeperis, Jonsson, and Sauer, 
1999). Further, the nucleoplasmin (NPM) family of proteins encompasses a group of 
nuclear chaperones that contain a conserved N-terminus within which lies a short acidic 
tract—a domain responsible for their oligomerization and chaperone function (Frehlick, 
Eirin-Lopez, and Ausio, 2007). These activities are most likely mediated by electrostatic 
interactions between the polyanions and client proteins. Finally, Daxx is a histone 
chaperone for the histone variant H3.3 that works with ATRX to assemble H3.3-
containing nucleosomes (Drane, Ouararhni, et al, 2010; Elsaesser, and Allis, 2010; 
Elsasser, Huang, et al, 2012; Lewis, Elsaesser, et al, 2010). Its interaction with H3.3 has 
been mapped to a region within the central portion of Daxx, partially encompassing the 
acid-rich region (Drane, Ouararhni, et al, 2010). It is possible that its histone chaperone 
activity extends beyond deposition of H3.3 into chromatin; Daxx may also be able to 
assist H3.3 to attain its native structure. Additionally, it has been shown that Daxx 
depletion leads to accumulation of a soluble pool of newly synthesized H3.3 in the 
nucleoplasm, preventing H3.3 from localizing to PML-NBs (Delbarre, Ivanauskiene, et al, 
2013). In their case, solubility refers to free H3.3 in nucleoplasm or cytoplasm. The idea 
that Daxx can associate with newly synthesized proteins is reminiscent of the co-
translational folding activity of some of the molecular chaperones.  
In the current study, we hypothesize that Daxx is a novel molecular chaperone.  
We found that Daxx has refolding activity toward denatured luciferase and wild-type p53. 
Daxx can also increase the solubility and activity of luciferase upon heat shock both in 
vitro and in vivo.  Deletion mutant analysis reveals that not only is the acid-rich region of 
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Daxx important for its protein folding activity, but also a paired amphipathic helical 
domain near its N-terminus. These results indicate that Daxx is a candidate as a novel 
molecular chaperone that has the ability to refold misfolded protein species. This activity 
may also underlie the diverse set of proposed functions for Daxx.  
RESULTS 
Daxx can increase protein levels of luciferase in a transcription- and Hausp-
independent manner 
 
A commonly used substrate for the assaying of protein folding is luciferase. 
Luciferase is highly thermolabile and its activity can be easily monitored using 
luminescence. To examine the possibility that Daxx has an effect on luciferase 
expression in vivo, we expressed Flag-NLS-luciferase (where NLS is a nuclear 
localization sequence), Flag-Daxx, and GFP-Hsp70 in U2OS cells, as indicated (Figure 
3.1A). Upon Daxx overexpression, luciferase protein levels increased in a dose-
dependent manner; however, luciferase levels were unchanged upon Hsp70 
overexpression, as seen previously (Kampinga, Kanon, et al, 2003) (Figure 3.1A, lane 6 
vs. lanes 3-5).  To exclude the possibility that Daxx was affecting the transcription of 
luciferase, Flag-Daxx was expressed with Flag-NLS-luciferase for both qPCR (Figure 
3.1B) and western analysis (Figure 3.1C). Daxx overexpression had little effect on 
luciferase gene expression, but did increase luciferase protein levels (Figure 3.1C, lanes 
2 and 3).  
Daxx is known to form a complex with Hausp, which leads to stabilization of 
Mdm2 via the deubiquitinase activity of Hausp (Tang, Qu, et al, 2006). To examine if the  
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Figure 3.1. Daxx can increase protein levels of luciferase in a transcription-
independent manner.  
(A) U2OS cells were transfected with Flag-NLS-luciferase and increasing amounts of 
Flag-Daxx or GFP-Hsp70, as indicated. Cell lysates were analyzed by western blot. (B, 
C) The increase of luciferase expression is not dependent upon Daxx-mediated 
transcription. U2OS cells were transfected with Flag-NLS-luciferase and increasing 
amounts of Flag-Daxx concurrently for mRNA analysis via qPCR (B) and for protein 
analysis via western (C). 
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Daxx-Hausp interaction had a role in luciferase stabilization, we treated H1299 cells with 
Hausp or control siRNA and expressed increasing amounts of Daxx. The ability of Daxx 
to increase luciferase protein levels was unaffected by Hausp knockdown (Figure 3.2, 
lanes 5-6 vs. 2-3). These results show that Daxx can increase luciferase protein levels in 
vivo in a transcription- and Hausp-independent manner.  
Daxx can renature heat-denatured luciferase in vitro 
The observation that Daxx could increase luciferase protein levels in cells led us 
to posit that Daxx may have chaperone-like effects in vitro. To test this, we constructed a 
double-tagged Daxx with a glutathione-S-transferase (GST) tag at the N-terminus and a 
poly-histidine (6xHis) tag at the C-terminus. This Daxx fusion protein was purified from 
bacteria using a tandem-affinity approach followed by ion-exchange chromatography 
(Figure 3.3, A and B). To confirm the purity of Daxx, all bands that were visible by 
Coomassie staining were sent for mass spectrometry analysis (Figure 3.3B, lane 2). All 
bands were identified as Daxx, underscoring the purity of our purified Daxx. Upon 
confirmation that Daxx was pure, we performed traditional chaperone assays.  
One characteristic of conventional chaperones, including those of the Hsp70/40 
family, is their ability to prevent the denaturation of substrates. To perform this 
experiment, luciferase was concurrently incubated at 42ºC with GST and lysozyme as 
negative controls, Daxx (denoted as Daxx-His hereafter), and Hsp70/40 with ATP as a 
positive control. Daxx was unable to prevent loss luciferase of activity; however, the 
combination of Hsp70/40 was able to prevent denaturation of luciferase, as expected 
(Kubo, Tsunehiro, et al, 1999) (Figure 3.4A). For the same experiment when the 
Hsp70/40 data was removed from analysis, we were able to better see the kinetics of 
luciferase activity upon incubation with the other proteins. Strikingly, it seemed that Daxx  
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Figure 3.2. Daxx can increase protein levels of luciferase in a Hausp-independent 
manner.  
Increasing amounts of Flag-Daxx were transfected with Flag-NLS-luciferase into H1299 
cells. The cells were then treated with control or Hausp siRNA and analyzed by western 
blot. Actin and GFP are shown as controls for loading and transfection efficiency, 
respectively. 
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Figure 3.3. Protocol for Daxx purification.  
(A) Schematic illustrating purification scheme when GST cleavage was required. When it 
was not required, that step was switched with protein elution using GSH. (B) Coomassie-
stained gel depicting purity of Daxx-His before and after ion-exchange (IEX) 
chromatography.  
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Figure 3.4. Daxx cannot prevent denaturation of luciferase in vitro.  
(A) Heat-denatured luciferase (5 nM) was incubated with LRB or 50 nM GST, lysozyme, 
Daxx, or Hsp70/40 supplemented with 10 mM ATP at 42ºC. Luciferase activity readings 
were taken at the indicated times normalized to an undenatured control and represent 
the means + SEM (n = 3). (B) Graph represents same data as in (A) except without 
Hsp70/40 and zero time point data.  
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was accelerating the denaturation of luciferase (Figure 3.4B), as luciferase had virtually 
zero activity by five minutes, whereas the other conditions retained approximately 10% 
of initial luciferase activity by five minutes. This result indicates that Daxx cannot prevent 
the denaturation of luciferase; rather, it accelerates luciferase denaturation. 
Another characteristic of chaperones is that they are able to promote the 
refolding of denatured proteins. To assess this, luciferase was first denatured at 42ºC 
and then distributed to reactions containing buffer, lysozyme as a negative control, Daxx, 
or Hsp104/70/40 with ATP as a positive control. We used the Hsp104/70/40 system as a 
positive control as this has previously been shown to be effective in the renaturation of 
denatured substrates, such as luciferase and β-galactosidase (Glover, and Lindquist, 
1998). Daxx was able to efficiently renature heat-denatured luciferase in vitro at 15- 
(Daxx-His +) and 25-fold (Daxx-His ++) excess of the luciferase concentration, albeit to a 
lesser extent than Hsp104/70/40 (Figure 3.5A). To further analyze the effect of Daxx on 
luciferase, a sedimentation assay was performed where denatured luciferase was 
incubated with buffer, lysozyme, or Daxx. The reactions were then centrifuged and 
separated into supernatant, containing soluble luciferase, and pellet, containing insoluble 
luciferase, fractions. The results indicate that Daxx was able to solubilize heat-denatured 
luciferase aggregates, as more luciferase was visible in the soluble fraction when Daxx 
was present (Figure 3.5B). Although with lysozyme it appeared that there was no 
luciferase in the pellet, lysozyme was not solubilizing luciferase, as it was not visible in 
the soluble fraction. This implies that the insoluble luciferase was part of an SDS-
insoluble fraction that cannot be resolved using SDS-PAGE. Together, these results 
suggest that Daxx is not able to prevent the denaturation of luciferase, but it is able to 
promote the renaturation of an already denatured substrate.  
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Figure 3.5. Daxx can renature heat-denatured luciferase in vitro.  
(A) Heat-denatured luciferase (5 nM) was incubated with lysozyme (125 nM), Daxx (75 
nM or 125 nM), and Hsp104/70/40 (125 nM) supplemented with 10 mM ATP at 25°C. 
Luciferase activity was read at the indicated times and expressed as fold change over 
undenatured control. Values represent means + SEM (n = 3). (B) Heat-denatured 
luciferase (5 nM) was incubated with lysozyme (120 nM) and Daxx (30-120 nM) for 3 h 
at 25°C and then partitioned into soluble and insoluble fractions via sedimentation at 
17,000 x g for 15 min. Fractions were analyzed via western blot.  
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To examine if Daxx had activity towards luciferase in vivo, we expressed Flag-
Daxx, Flag-NLS-luciferase, and GFP-Hsp70 in H1299 cells and performed an in vivo 
luciferase assay (Michels, Kanon, et al, 1997) (Figure 3.6, A and B). In this assay, the 
cells were first treated with cycloheximide to prevent the translation of endogenous 
chaperone proteins upon heat shock. The cells were then heat shocked and allowed to 
recover at 37ºC. Although Daxx did not protect luciferase during heat shock, and in fact 
accelerated its loss of activity, it was able to recover it to a greater proportion (when 
compared to heat shock activity) than luciferase alone or when luciferase was expressed 
with Hsp70 (Figure 3.6A). The inability of Hsp70 to strongly recover luciferase activity 
was not unexpected. It has been shown that Hsp70 is not as effective in renaturation of 
luciferase in the nucleus as compared to the cytoplasm (Nollen, Brunsting, et al, 1999). 
Additionally, Daxx was also able to increase the protein levels of luciferase under 
control, heat shock, and recovery conditions (Figure 3.6B), confirming our earlier results 
(Figure 3.1A). This evidence suggests that Daxx cannot prevent the denaturation of 
luciferase; rather, it accelerates denaturation. It is then able to refold the denatured 
luciferase in vivo to a greater proportion than heat shock proteins.  
Daxx can refold misfolded luciferase, but not higher molecular weight aggregates 
 
On the basis that Daxx could renature heat-denatured luciferase, we sought to 
determine the physical properties of our luciferase substrate. To determine this, we used 
size fractionation to visualize the distribution of differentially formed aggregates via urea 
or heat denaturation. After denaturation, luciferase was applied to a gel filtration column 
for size fractionation. Fractions were collected and assessed for distribution using 
western blotting. When luciferase was denatured using heat denaturation, most of the 
luciferase eluted at later fractions, indicative of oligomeric, dimeric, and monomeric  
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Figure 3.6. Daxx accelerates denaturation of luciferase and enhances recovery of 
luciferase in vivo.  
(A, B) H1299 cells were transfected with luciferase and concurrently with either empty 
vector, Flag-Daxx, or GFP-Hsp70. Cells were then treated with CHX for 30 min to 
prevent translation of new chaperone proteins. Control samples were kept at 37°C for 
duration of assay while heat shock and recovery samples were placed at 45°C for 30 
min, after which the recovery samples were placed back at 37°C for 3 h. (A) Luciferase 
activity is displayed relative to control samples. Values represent means + SEM (n = 4, 
triplicate sampling). (B) Western analysis shows representative samples from each 
condition and experiment.  
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Figure 3.7. Daxx can renature heat-denatured luciferase.  
(A, B) Heat-denatured luciferase (1 µM) was fractionated via gel filtration at 4ºC. The 
elution profile was determined via western blotting (B). For refolding, column fractions in 
the range of 2000 kDa-44 kDa were incubated with LRB, or 100 nM lysozyme, Daxx, or 
Hsp104/70/40 supplemented with 10 mM ATP for 90 min at 25°C at which point 
luciferase activity was determined (A).  
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states (Figure 3.7, A and B). Selected elution fractions were then incubated with buffer, 
lysozyme, Daxx, or Hsp104/70/40 and luciferase activity was measured after 90 minutes 
of refolding. Daxx was able to efficiently renature luciferase when compared to lysozyme 
and the buffer control. The Hsp104/70/40 system had very strong reactivation ability, as 
expected (Glover, and Lindquist, 1998). However, when urea-denatured luciferase was 
size fractionated, Daxx was not able to disaggregate the higher molecular weight 
aggregates, which eluted at much earlier fractions than the heat-denatured luciferase 
(Figure 3.8, A and B). Hsp104/70/40 was able to efficiently renature the urea-denatured 
aggregates, as expected. These data indicate that Daxx can refold misfolded proteins, 
but it cannot disaggregate higher molecular weight aggregates.  
The PAH2 and acid-rich domains of Daxx are important for its activity  
 
Preliminary data indicated that the acid-rich and PAH2 domains of Daxx were 
most important for its activity toward luciferase. Based upon these findings, we 
constructed mutants that either did not express both the PAH2 (residues 157-260) and 
D/E (residues 414-505) domains (denoted as DaxxΔΔ), or only expressed the PAH2 or 
D/E domain (Figure 3.9, A-E). All of these Daxx mutants were constructed in the same 
vector as the full-length Daxx and purified using a similar method. When the GST tag 
was cleaved from the PAH2 and D/E domains, the proteins were unable to be purified. 
Thus, for those fragments we retained the GST tag and its activity was compared to full-
length Daxx with an intact GST tag.  
When DaxxΔΔ was assayed for activity in a luciferase renaturation assay (as in 
Figure 3.5), it was not able to renature heat-denatured luciferase (Figure 3.10A). When 
the D/E or PAH2 domain were tested alone, they were unable to efficiently renature  
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Figure 3.8. Daxx cannot renature higher molecular weight aggregates.  
(A, B) Urea denatured luciferase (1 µM) was fractionated via gel filtration at 4ºC. The 
elution profile was determined via western blotting (B). For refolding, column fractions in 
the range of 2000 kDa-44 kDa were incubated with LRB, or 100 nM lysozyme, Daxx, or 
Hsp104/70/40 supplemented with 10 mM ATP for 90 min at 25°C at which point 
luciferase activity was determined (A).  
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Figure 3.9. Purification of Daxx mutants.  
(A) Schematic depicting structural domains of Daxx. PAH – paired amphipathic helices; 
CC – coiled coil domain; D/E – acid-rich region; S/P/T – serine/proline/threonine-rich 
region. Asterisks indicate deleted or isolated regions. (B-E) Coomassie-stained gels of 
proteins purified after tandem-affinity purification and IEX chromatography. For smaller 
fragments, GST-tag was retained due to loss of purification ability upon cleavage of tag. 
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Figure 3.10. PAH2 domain and acid-rich region (D/E) are necessary for Daxx to 
renature heat-denatured luciferase in vitro.  
(A) Deletion of PAH2 and D/E regions leads to loss of renaturation ability. Heat-
denatured luciferase (5 nM) was incubated with 125 nM GST, lysozyme, DaxxΔΔ, Daxx, 
or Hsp104/70/40 supplemented with 10 mM ATP at 25ºC. (B) Mutants comprising only 
the PAH2 (250 nM) or D/E (250 nM) region were tested either alone or in combination 
for their ability to renature heat-denatured luciferase (5nM). For (B) and (C), luciferase 
activity was read at the indicated times and expressed as fold change over an 
undenatured control. Values represent means + SEM (n = 3).   
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luciferase; however, when they were combined at equimolar ratios, there was a 
synergistic reactivation effect upon denatured luciferase (Figure 3.10B). This suggests 
that both domains are required for activity, but they are not sufficient on their own. To 
confirm that these domains and full-length Daxx were able to interact directly with 
luciferase, we purified Daxx, D/E and PAH2 fused only to GST. In an in vitro pull-down 
assay, immobilized GST-Daxx, -D/E, and -PAH2, but not GST alone, were able to pull 
down recombinant Flag-NLS-luciferase (Figure 3.11), indicating that full-length Daxx and 
the D/E and PAH2 domains are able to directly interact with luciferase.   
Daxx preferentially acts upon misfolded luciferase 
 
To examine in vivo if Daxx had any effect on misfolded luciferase, we examined 
whether Daxx could affect the protein levels of insoluble luciferase. Upon transfection of 
Flag-Daxx with Flag-NLS-luciferase in H1299 cells, the cells were treated with 
cycloheximide to inhibit new protein synthesis and the protein levels of insoluble 
luciferase were analyzed (Figure 3.12, A and B). As shown by densitometry analysis, the 
protein levels of insoluble luciferase decreased over time upon Daxx overexpression, 
indicating that Daxx was able to solubilize the insoluble luciferase. We were unable to 
detect a concomitant increase in the protein levels of soluble luciferase, most likely 
because the insoluble fraction comprises a very small portion of the total luciferase. 
Thus, any changes in the soluble fraction are not sensitive enough to be detected by 
western blot.   
To determine if this effect translated to enhanced binding of Daxx to misfolded 
luciferase, a co-immunoprecipitation assay was performed. H1299 cells were transfected  
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Figure 3.11. Daxx and Daxx fragments can bind to luciferase in vitro.  
Recombinant Flag-NLS-luciferase purified from 293T cells was mixed with either lysis 
buffer, GST, GST-Daxx, GST-PAH2, or GST-D/E purified from bacteria. Two different 
amounts of Daxx and its mutants were used for immunoprecipitation. Input and IP were 
analyzed by SDS-PAGE and western blot using anti-luciferase antibody for luciferase 
and anti-GST antibody for GST, Daxx, and Daxx mutants. FL-full-length Daxx; D-acid-
rich region; P-PAH2 domain.  
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Figure 3.12. Daxx can decrease the protein levels of insoluble luciferase.  
(A) H1299 cells were transfected with Flag-NLS-luciferase with or without Flag-Daxx. 
The cells were treated with CHX (50 µg/mL) for the indicated times. Both the 
supernatant and pellet fractions were collected; however, only the pellet fraction was 
analyzed for luciferase. Samples were analyzed via western blot and using densitometry 
analysis (ImageJ), the luciferase to actin ratio was determined and plotted as a function 
of time (B).  
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with HA-Daxx with or without Flag-NLS-luciferase and subjected to heat shock as in 
Figure 3.6. Upon heat shock, more Daxx precipitated with luciferase than in the control 
condition (Figure 3.13A, lane 4 vs. 3). We confirmed that the heat shock of luciferase 
was effective by testing the activity of the samples containing luciferase prior to 
immunoprecipitation. The luciferase activity did decrease upon heat shock (Figure 
3.13B). To further test this idea, we used an aggregation-prone luciferase mutant (Flag-
nDMFluc-GFP) (Gupta, Kasturi, et al, 2011). When wild-type (Flag-nFluc-GFP) and 
mutant luciferase were immunoprecipitated, Daxx bound more strongly to the mutant 
luciferase, even though it precipitated less effectively than the wild-type luciferase 
(Figure 3.14). These results suggest that Daxx preferentially binds to misfolded 
luciferase.  
Daxx can solubilize p53 in vitro and in vivo 
Since luciferase is not found in human cells, we sought to find a physiologically 
relevant target of Daxx. It has been established by us and other groups that Daxx can 
regulate p53 (Gostissa, Morelli, et al, 2004; Tang, Qu, et al, 2006; Tang, Agrawal, et al, 
2013; Zhao, Liu, et al, 2004). We repeated a similar experiment to Figure 3.5B; we 
purified Flag-p53 from mammalian cells and denatured it at 37ºC for 3-4 min to induce 
misfolding (Figure 3.15A). Upon addition of increasing amounts of Daxx, p53 was 
solubilized and shifted to the supernatant fraction (Figure 3.15A, lanes 3-6 vs. 1). The 
addition of lysozyme seemed to increase the misfolding of p53 as more p53 was found 
in the pellet fraction, similar to our result from Figure 3.5B and it was not able to 
solubilize p53 as p53 was not detected in the supernatant fraction. To test if Daxx could 
also stabilize p53 in vivo, we utilized p53 -/- Mdm2 -/- MEFs to eliminate the effect Daxx 
has on Mdm2. When Flag-Daxx was transfected in increasing amounts with steady  
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Figure 3.13 Daxx can preferentially associate with heat-denatured luciferase.  
(A, B) Daxx preferentially binds to luciferase upon heat shock. H1299 cells were 
transfected with HA-Daxx and Flag-NLS-luciferase as indicated. Cells were then treated 
with CHX (50 µg/mL) for 30 min. Control samples were kept at 37°C for the duration of 
the assay while heat shock and recovery samples were placed at 45°C for 30 min, after 
which the recovery samples were placed back at 37°C for 3 h. Cell lysates were 
incubated with anti-Flag M2 beads and input and IP samples were analyzed by western 
blot (A). Luciferase activity was determined for samples with luciferase prior to 
immunoprecipitation (B).  
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Figure 3.14. Daxx preferentially associates with an aggregation-prone luciferase 
mutant.  
H1299 cells were transfected with HA-Daxx with Flag-nFluc-GFP or Flag-nDMFluc-GFP, 
an aggregation-prone mutant of luciferase, as indicated. Cell lysates were incubated with 
anti-Flag M2 beads and input and IP were analyzed by western blot. Asterisk indicates 
non-specific band. 
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Figure 3.15. Daxx can renature p53 in vitro and in vivo.  
(A) Heat-denatured p53 aggregates (35 nM) were incubated at 25°C for 3 h with 
lysozyme (100 nM), or Daxx (12.5 nM-100 nM). Reactions were then partitioned into 
soluble and insoluble fractions via sedimentation at 17,000 x g for 15 min. (B) p53 -/- 
Mdm2 -/- MEFs were transfected with increasing amounts of Flag-Daxx and two different 
amounts of Flag-p53. Samples were analyzed via SDS-PAGE and western blot.  
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states of Flag-p53, it was able to increase the protein levels of p53 (Figure 3.15B, lanes 
2-3 vs. 1 and lanes 5-6 vs. 4). Together, these results suggest the Daxx is able to 
stabilize p53, when Mdm2 is not present, both in vitro and in vivo.  
Overall, these results indicate that Daxx has the ability to interact with misfolded 
proteins and can assist in the renaturation of denatured substrates. This newly 
discovered function for Daxx might have great implications in terms of finding an 
explanation as to the many demonstrated functions of Daxx. It is possible that Daxx 
interacts with so many proteins in order to regulate their folding. In-depth discussion of 
these results can be found in chapter five.  
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MATERIALS AND METHODS 
Antibodies, plasmids, and proteins – Antibodies for the following proteins/epitopes were 
purchased from the indicated sources: actin (A2066) and Flag (mouse monoclonal, M2, 
free (F3165) and conjugated to beads (A2220), HRP-conjugated (A8592), rabbit 
polyclonal (F7425)) (Sigma); GFP (JL-8, Clontech); Hausp/USP7 (A300, Bethyl 
Laboratories, Inc.); HA conjugated to HRP (Roche); luciferase (OB09, Calbiochem); 
Daxx (04-445, Millipore); p53 conjugated to HRP (DO-1, Santa Cruz Biotechnology). 
Plasmids encoding HA- or Flag-tagged Daxx and luciferase for transient transfection 
were made in pRK5. The luciferase plasmid was modified via addition of the SV40 
nuclear localization signal (NLS) PKKKRKV and a Leu550-to-Ile mutation that abolishes 
the lysosomal localization of luciferase. Flag-nFluc-GFP and Flag-nDMFluc-GFP were 
modified from plasmids generously provided by Dr. S. Rayachaudhari (Gupta, Kasturi, et 
al, 2011). GFP-Hsp70 was constructed in the pEGFP-C3 vector. pGEX-GST-Daxx-His 
was constructed using a pGEX vector modified with a Tobacco Etch Virus cleavage site 
(ENLYFQ) between the GST tag and the N-terminus of Daxx and using PCR for Daxx 
and the 6xHis tag. All Daxx mutants were constructed similarly into the same modified 
pGEX vector. DaxxΔΔ was constructed using the QuikChange Site Directed 
Mutagenesis Kit (Agilent). Hsp104 was a kind gift from the lab of Dr. James Shorter. Hsp 
70 and 40 were purchased from Enzo Life Sciences. 
Protein purification – The pGEX-GST-Daxx-His vector was transformed into Rosetta 2 
(Novagen) competent cells and resulting transformants were grown in 20 L LB medium, 
supplemented with 100 µg/mL ampicillin, for 14-16 h until they reached an OD600 of 0.5. 
Cultures were induced with 0.1-0.4 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 
4 h at 27ºC. Cells were collected via centrifugation and the pellet was lysed with Ni-NTA 
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lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole at pH 8.0 containing 
fresh 1 mM PMSF, 2 mM DTT, and 1 mg/mL lysozyme) followed by sonication for 20 
min. Lysates were either stored at -80ºC until needed or immediately incubated with 
GST beads (GE Healthcare) for 4 h to overnight at 4ºC. Beads were then washed with 
IP lysis buffer (20 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 0.5% NP-
40, and 10% glycerol) twice,  IP lysis buffer containing 0.5 M KCl once, IP lysis buffer 
containing 1.0 M KCl once, IP lysis buffer twice and AcTEV (Invitrogen) buffer (50 mM 
Tris-HCl at pH 8.0 and 0.5 mM EDTA) once. The beads were then incubated at 25ºC for 
2-3 h with AcTEV protease (Invitrogen) in AcTEV buffer supplemented with 25 mM DTT. 
The supernatant was collected and incubated with Ni-NTA beads (Invitrogen) for 2-4 h at 
4ºC. The beads were then washed with Ni-NTA wash buffer (50 mM NaH2PO4, 10 mM 
NaCl, and 10 mM imidazole at pH 7.0) three times and eluted with Ni-NTA elution buffer 
(50 mM NaH2PO4, 10 mM NaCl, and 500 mM imidazole at pH 7.0) for 1 h at 4ºC. The 
eluate was collected and subjected to IEX chromatography using a Mono Q column (GE) 
developed at a flow rate of 1 mL/min at pH 7.0. The protein was eluted from the column 
using a linear gradient of 10 mM – 1 M NaCl. Fractions were flash-frozen and stored at -
80ºC until needed. Proteins were purified to apparent homogeneity as determined by 
SDS-PAGE and Coomassie staining and the identity of specific bands was confirmed via 
mass spectrometry analysis. When GST-tag cleavage was not desired, GST beads were 
eluted with 35 mM reduced glutathione (GSH; Sigma) at pH 7.5 for 1 h at 4ºC and the 
rest of the purification was the same as above. Flag-tagged p53 was purified from 293T 
cells using (10) 10 cm plates. Cells were transfected with via calcium phosphate 
transfection method. 16 h later, cells were harvested using IP lysis buffer. Lysates were 
spun down at 17,000 x g for 15 min at 4ºC and supernatants were incubated with anti-
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Flag mAb beads for 4 h or overnight at 4ºC. After extensive washing, Flag-p53 was 
eluted using 3x Flag peptide (Sigma) for 1 h at 4ºC.  
Luciferase assays – For renaturation assays, firefly luciferase (Sigma) was heat 
denatured at 42ºC for 10-15 min and distributed to reactions at a final concentration of 5 
nM in luciferase refolding buffer (LRB: 25 mM HEPES-KOH at pH 7.4, 150 mM KAOc, 
10 mM MgAOc, and 10 mM DTT). For these reactions, GST and lysozyme were used as 
negative controls, Hsp104/70/40 was supplemented with ATP and ATP regeneration 
solution (Boston Biochem) and used as a positive control, and Daxx and mutants were 
added without ATP. For prevention of denaturation assays, luciferase (5 nM) was 
concurrently incubated with proteins at 42ºC and readings were taken at specified times. 
In both cases, triplicate reactions were made and luciferase readings were taken using 
the Luciferase Assay System (Promega) at indicated times using a Monolight 2010 
luminometer (Analytic Luminescence Laboratory). Activity was converted to fold change 
over native control via comparison to known quantities of an undenatured luciferase 
control. 
Sedimentation assays – Luciferase and p53 were denatured at 42ºC or 37ºC for 15 min 
or 5 min, respectively, and then distributed to reactions containing buffer (LRB for 
luciferase; PBS with 5 mM DTT for p53), lysozyme as a negative control, or Daxx. After 
3 h, the reactions were centrifuged at 17,000 x g for 15 min at 4ºC. The pellet and 
supernatant fractions were then resuspended in sample buffer and analyzed by SDS-
PAGE.  
Gel filtration – Luciferase (100 µM) was unfolded in 4 M Urea for 25 min at 30ºC and 
diluted 50-fold into cold LRB. Aggregates were then spun down at 17,000 x g for 10 min 
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at 4ºC. Then, 0.5 mL was loaded onto a 1 x 30 cm Superose 6 column (GE) equilibrated 
in LRB. Fractions (0.4 mL) were collected 15 min post-injection at a flowrate of 0.4 
mL/min. For heat-denatured luciferase, luciferase (1 µM) was incubated at 42ºC for 20 
min or until the luciferase activity was at least two magnitudes less than native control. 
Fractions were collected as for urea-denatured luciferase. For refolding in both 
instances, column fractions in the range of 2000 kDa-44 kDa were incubated with LRB, 
lysozyme (100 nM), Daxx (100 nM), or Hsp104/70/40 (100 nM) with ATP (10 mM) and 
incubated at 25°C. Luciferase activity was determined after 90 min of refolding.  
In vivo luciferase assay – H1299 cells were transfected with Flag-NLS-luciferase and 
either Flag-pRK5, Flag-Daxx, or GFP-Hsp70. After 16 h, cells were split in triplicate into 
24-well plates. 16 h later, cycloheximide (CHX) (50 µg/mL) was added to the cells for 30 
min. The heat shock and recovery plates were placed at 45ºC for 30 min after which the 
recovery plate was placed back at 37ºC for 3 h. Cells were lysed using Passive Lysis 
Buffer (Promega) and read using the Luciferase Assay System (Promega). Readings 
were normalized to the control sample of each group.  
Immunoprecipitation and western blot – Transfections were carried out using 
Lipofectamine 2000 (for DNA) or RNAiMAX (for siRNA) (Invitrogen) according to the 
manufacturer’s instructions. After treatments were complete, cells were lysed in IP lysis 
buffer, supernatant (50 mM Tris at pH 8.8, 100 mM NaCl, 5 mM MgCl2, 0.5% NP-40, and 
fresh 2 mM DTT, 250 IU/ml benzonase (Sigma), 1 mM PMSF, and 1x complete protease 
inhibitor cocktail) or pellet buffer (20 mM Tris at pH 8.0, 15 mM MgCl2, and fresh 2 mM 
DTT, 250 IU/ml benzonase, 1 mM PMSF, and 1x complete protease inhibitor cocktail) 
for fractionation analysis. Flag-NLS-luciferase was immunoprecipitated with anti-Flag 
mAb beads and analyzed by western blot using anti-Luc antibody (1:500) for luciferase 
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input, Flag-HRP antibody (1:1000) for luciferase IP, and HA-HRP antibody (1:5000) for 
Daxx input and IP.  
In vitro binding - Flag-NLS-luciferase was purified from 293T cells using anti-Flag mAb 
beads for 4 h to overnight at 4ºC and eluted with 3x Flag peptide for 1 h at 4ºC. GST, 
GST-Daxx, -D/E, and -PAH2 were constructed into pGEX with only a GST tag and 
purified similarly to pGEX-GST-Daxx-His proteins with omission of the His purification 
and IEX chromatography steps. Briefly, cleared lysates were incubated with GST beads 
for 4 h to overnight at 4ºC. After extensive washing, the beads were eluted with 30mM 
GSH at 4ºC for 1 h. Mixtures of luciferase (5 nM) and Daxx fragments were incubated at 
4ºC for 2 h after which a portion was taken for input. The rest of the reactions were 
incubated with GST beads previously blocked with 3% BSA for 1 h at 4ºC. Samples 
were washed three times with IP lysis buffer and beads were resuspended in sample 
buffer and analyzed by SDS-PAGE and western blot. Input and IP samples were blotted 
with luciferase antibody and anti-GST antibody for GST, Daxx and Daxx mutants.  
Quantitative RT-PCR analysis – Total RNA was isolated from cells using TRIzol 
(Invitrogen). Reverse transcription was performed using the First Strand cDNA Synthesis 
Kit (Marligen Biosciences). Primers used for luciferase amplification are as follows: 
forward primer 5’ – CAA CTG CAT AAG GCT ATG AAG AGA – 3’; reverse primer 5’ – 
ATT TGT ATT CAG CCC ATA TCG TTT – 3’. 
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CHAPTER 4:  THE ROLE OF DAXX IN CDK6 REGULATION 
 
INTRODUCTION 
Daxx has the ability to regulate cellular proliferation through its cell-cycle 
dependent expression patterns and functions. Daxx is translocated to heterochromatin 
during S phase of the cell cycle via association with ATRX. It is released from ATRX 
during G2 phase, suggesting that the Daxx-ATRX interaction is important for S phase 
progression. Furthermore, Daxx-deficient cells display an accelerated S phase (Ishov, 
Vladimirova, and Maul, 2004). Another study uncovered a role for Daxx in cell cycle 
progression where depletion of Daxx led to perturbations in the duration of mitotic stages 
(Giovinazzi, Lindsay, et al, 2012). They found that Daxx-depleted cells displayed a 
stabilization of cyclin B and though there was a faster progression through prophase, 
there was a prolongation of prometaphase/metaphase, indicating that Daxx is required 
for normal mitosis. Preliminary data from our lab indicate that Daxx knockdown 
abrogates cell growth in a p53-independent and -dependent manner (Figure 4.1, A and 
B). When Daxx is stably knocked down using shRNA in U2OS or the p53-null cell line 
H1299, there is an abrogation of proliferation. Decrease in cellular proliferation in the 
p53 wild-type cells can be explained by the role of Daxx in Mdm2 stabilization (Tang, 
Qu, et al, 2006); however, the mechanism by which Daxx can regulate proliferation 
independent of p53 remains elusive. While investigating targets of Daxx using 
microarray analysis in human colon carcinoma (HCT116 p53 +/+) cells, we found that in 
Daxx-depleted cells, a cell cycle regulator, cyclin-dependent kinase 6 (Cdk6), was the 
most strongly downregulated gene (Figure 4.2).  
Cdk6 was first identified as a novel member of the vertebrate family of Cdk1 
kinases (Meyerson, Enders, et al, 1992). It was found to possess kinase activity toward  
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Figure 4.1. Daxx-depletion leads to abrogation of cell growth in a p53-independent 
manner.  
(A, B) U2OS and H1299 (p53-deficient) cells were used to create stable cell lines 
expressing pLKO.1 or Daxx-shRNA and assessed for proliferation ability (n = 2) (A) and 
protein expression (B).  
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Figure 4.2. Heat map depicting microarray analysis of Daxx-depleted HCT116 p53 
+/+ cells.  
Yellow box highlights downregulation of Cdk6 expression upon Daxx silencing. Figure 
courtesy of Aaron Stonestrom. 
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pRb and partner with the G1 phase cyclins, allowing for progression through the cell 
cycle (Meyerson, and Harlow, 1994). Cdk6 shares almost 71% homology with Cdk4 and 
both are able to bind to cyclins D1, D2, and D3 during G1 phase to phosphorylate pRb 
(Grossel, and Hinds, 2006). Both are ubiquitously expressed and are generally 
considered functionally redundant (Grossel, and Hinds, 2006). However, recent 
evidence indicates that Cdk6 has functions distinct from those of Cdk4 and can have a 
role beyond cellular proliferation. 
Many studies have emerged implicating Cdk6 as a regulator of differentiation in a 
variety of cell types. For example, Cdk6 can block differentiation of murine 
erythroleukemia (MEL) cells and its downregulation is required for MEL cells to reinitiate 
differentiation (Matushansky, Radparvar, and Skoultchi, 2003). The entry of MEL cells 
into terminal differentiation is accompanied by a decrease in Cdk2 followed by a decline 
in Cdk6 activity and inhibitors against Cdk2 and Cdk6 can trigger differentiation. 
Importantly, inhibitors against Cdk4 or an inhibitor-resistant form of Cdk4 cannot cause 
differentiation of these cell types, providing a functional difference between Cdk6 and 
Cdk4 (Matushansky, Radparvar, and Skoultchi, 2000). Further, it was shown that Cdk6 
downregulation is essential for BMP-2-mediated osteoblast differentiation (Ogasawara, 
Kawaguchi, et al, 2004). Overexpression of Cdk6, but not Cdk4, led to inhibition of 
differentiation of the osteoblasts. Interestingly, this study found that Cdk6 did not 
influence the proliferation of the osteoblasts and had no effect on their progression 
through the cell cycle. Finally, Cdk6 is essential for Notch-dependent T-lineage survival, 
proliferation, and differentiation (Hu, Deshpande, et al, 2009).  Cdk6, though ubiquitously 
expressed, is most abundant in lymphoid organs (Meyerson, Enders, et al, 1992; 
Meyerson, and Harlow, 1994). It has predominant expression in hematopoietic cell types 
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and is overexpressed in human T-cell lymphoblastic leukemia (T-ALL), suggesting a role 
for Cdk6 in thymocyte malignancies (Chilosi, Doglioni, et al, 1998; Della Ragione, 
Borriello, et al, 1997). The study by Hu, et al found that Cdk6 -/- mice had a reduction in 
thymocyte numbers in all compartments, consistent with the observation that Cdk6 -/- 
mice have defective thymic development (Malumbres, Sotillo, et al, 2004). It was found 
that Cdk6 is required for Notch-dependent proliferation, survival and differentiation. 
Together, these results suggest that Cdk6 has cell cycle-independent functions. 
While Cdk6 is presumed to be a promoter of cellular proliferation, Cdk6 can also 
inhibit proliferation in a specific subset of cells. NIH 3T3 cells that stably overexpress 
Cdk6 proliferated at a significantly slower rate than when the cells concurrently 
overexpressed Cdk6 and a dominant negative form of Cdk6, indicating that Cdk6 was 
inhibiting cell growth (Nagasawa, Gelfand, and Lucas, 2001). Additionally, Cdk6 can 
inhibit the proliferation of some human mammary epithelial (HMEC) cells (Lucas, 
Domenico, and Gelfand, 2004). This study showed that breast-tumor derived cell lines 
had reduced levels of Cdk6 protein while primary HMECs had high levels of Cdk6. 
Overexpression of Cdk6 in the tumor cell lines led to reduced growth rates; when ectopic 
expression of Cdk6 was lost, they were able to proliferate more rapidly.  
The roles of Cdk6 in differentiation and anti-proliferation indicate that Cdk6 is 
more than a mediator of the cell cycle. Understanding the regulation of Cdk6 would 
provide new insight into how cellular differentiation occurs and how cancer cells 
downregulate the growth-inhibitory effects of Cdk6 to promote proliferation. Based upon 
our microarray analysis showing that Cdk6 was strongly downregulated upon Daxx 
depletion and that Daxx may have p53-independent functions related to cellular 
proliferation, we focused our efforts on the regulation of Cdk6 by Daxx.  
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RESULTS 
Daxx depletion leads to lower protein levels of Cdk6 in a variety of cell lines 
To confirm the microarray result where Daxx depletion in HCT116 p53 +/+ cells 
led to downregulation of Cdk6 (Figure 4.2), an array of cancer cell lines were treated 
with control or Daxx siRNA and assessed for Cdk6 expression. When Daxx was 
depleted in U2OS or isogenic HCT116 p53 +/+ and p53 -/- cells, Cdk6 protein levels 
were also dramatically reduced (Figure 4.3, A and B). This effect was also seen when 
the primary cell lines, IMR90 (human fetal lung fibroblasts) and MEFs (mouse embryonic 
fibroblasts) were used for analysis (Figure 4.3, C and D). Conversely, overexpression of 
Daxx in HCT116 p53 +/+ cells correlated with higher Cdk6 protein levels, albeit it was 
not a very robust effect (Figure 4.4A). A rescue experiment was performed using 
HCT116 p53 +/+ cells where Daxx was stably knocked down using shRNA. After 
establishing the stable cell line, Flag-Daxx was transiently overexpressed and Cdk6 
levels were assessed. Upon expression of exogenous Daxx, Cdk6 levels were higher 
than when Daxx was depleted indicating that Daxx can modulate Cdk6 protein levels 
(Figure 4.4B, lanes 2-4 vs. 1).  
To determine if the effect of Daxx was specific to Cdk6, we examined the 
expression of various cell cycle markers upon Daxx depletion. We examined the levels 
of Cdk2, Cdk4, cyclin D1, and Rb (Figure 4.5, A and B) in a variety of cancer cell lines. 
These proteins were minimally affected by Daxx knockdown suggesting that the effect of 
Daxx was specific for Cdk6.  
Daxx affects transcription of Cdk6 
 
 To test if Daxx was regulating the stability of Cdk6 via a degradation-dependent  
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Figure 4.3. Cdk6 protein levels decrease upon Daxx silencing.  
U2OS (A) HCT116 p53 +/+ and -/- (B) and IMR90 (C) cells were treated with control or 
Daxx siRNA and analyzed for Cdk6 expression via western blot. (D) Daxx +/+ or Daxx -/- 
MEFs were assessed for Cdk6 expression via western blot.  
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Figure 4.4. Daxx overexpression increases Cdk6 protein levels.  
(A) Flag-Daxx was transfected in HCT116 +/+ cells and analyzed by western blot for 
Cdk6. Daxx levels were assessed using anti-Daxx antibody. (B) HCT116 p53 +/+ cells 
stably expressing Daxx shRNA were transfected with increasing amounts of Flag-Daxx 
and assessed for Cdk6 levels. Daxx expression was confirmed separately by anti-Daxx 
and anti-Flag antibodies.  
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Figure 4.5. Daxx does not affect protein levels of other cell cycle regulators.  
(A) U2OS, Saos-2, and HCT116 p53 +/+ cells were treated with control or Daxx siRNA 
and analyzed by western blot for Cdk2 and Cdk6 expression. (B) Isogenic HCT116 p53 
+/+ and p53 -/- cells were Daxx-depleted and assessed for Rb, cyclin D1, and Cdk4 
expression.  
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mechanism, we used MG132, a proteasome inhibitor, in combination with Daxx siRNA 
and examined Cdk6 protein levels in various cancer cell lines. We analyzed Mdm2 levels 
as an internal control for the effectiveness of MG132 treatment, as Mdm2 is very 
sensitive to proteasome-mediated degradation. We observed that with MG132 
treatment, Mdm2 levels increased indicating that MG132 was inhibiting the proteasome 
and in turn Mdm2 degradation (Figure 4.6). Daxx silencing led to lower Cdk6 levels, yet 
Cdk6 levels were only marginally altered in the presence of MG132, regardless of Daxx 
siRNA treatment. This is not completely unexpected, as Cdk levels remain fairly constant 
during the cell cycle (Sherr, 2000; Vermeulen, Van Bockstaele, and Berneman, 2003). 
This result suggests that Daxx is not regulating Cdk6 levels via a degradation-dependent 
mechanism.  
 To further test if Daxx was controlling the stability of Cdk6 protein, cycloheximide 
was used to inhibit new protein synthesis in HCT116 p53 -/- cells to determine changes 
in Cdk6 half-life in the absence of Daxx. When Daxx was silenced via siRNA treatment, 
there were lower overall levels of Cdk6. To fairly compare the half-life of Cdk6 upon 
Daxx knockdown, we analyzed two different exposures of Cdk6 where the zero hour 
time points appeared most equal (Figure 4.7, lanes 5-8 vs. 1-4). After comparison of the 
different exposures, it was clear that Daxx depletion had little effect on the half-life of 
Cdk6. Together, these results indicate that Daxx does not affect the protein stability of 
Cdk6.  
 To further elucidate the mechanism by which Daxx was affecting Cdk6 protein 
levels, we examined if Daxx affected Cdk6 transcription. Human cervix adenocarcinoma 
(HeLa) and H1299 cells were treated with Daxx siRNA and analyzed via western blot, 
RT-PCR and quantitative RT-PCR (Figure 4.8, A-C). Daxx-depleted cells displayed  
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Figure 4.6. Daxx does not affect protein stability of Cdk6.  
H1299, HeLa, and HCT116 p53 +/+ were treated with control or Daxx siRNA. 16 h later, 
cells were treated with MG132 (20 µM) for 4 h. Samples were harvested and analyzed 
via western blot.  
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Figure 4.7. Daxx does not affect half-life of Cdk6.  
HCT116 p53 -/- cells were depleted of Daxx using siRNA. 16 h later, cells were treated 
with CHX (50 µg/mL) for the indicated times. After harvesting and lysis, samples were 
analyzed for Cdk6 expression via western blot. Two different exposures of Cdk6 are 
shown where band intensity at the zero time points is most comparable.  
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Figure 4.8. Daxx affects transcription of Cdk6.  
H1299 and HeLa cells were treated with control or Daxx siRNA and assessed for protein 
(A) and mRNA levels using RT-PCR (B) and qPCR (C).  
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lower levels of Cdk6 protein (Figure 4.8A) and mRNA (Figure 4.8, B and C) suggesting 
that Daxx was able to regulate the transcription of Cdk6. To expand the transcriptional 
regulatory role of Daxx, we performed chromatin immunoprecipitation (ChIP) to assess 
whether Daxx associates with the endogenous Cdk6 promoter (Figure 4.9). For this 
experiment, HCT116 p53 +/+ cells were subject to chemical crosslinking followed by 
immunoprecipitation of Daxx and analysis of associated DNA via qPCR using gene-
specific primers (see materials and methods for sequences). The results are shown as 
relative input units to account for background signal and input chromatin. The ChIP 
assay reveals that Daxx bound to the Cdk6 promoter with some specificity, as it was not 
associated with the actin promoter. p53 was immunoprecipitated as a positive control 
and it bound to the p21 promoter, as expected. Daxx signal was most enriched at the -
700 bp region of the Cdk6 promoter. Interestingly, there is a potential binding NF-κB 
binding site at this region of the Cdk6 promoter (Cram, Liu, et al, 2001) and Daxx has 
previously been shown to modulate transcription of NF-κB target genes (Michaelson, 
and Leder, 2003; Park, Lee, et al, 2007). We also observed enrichment of Daxx at the -1 
kb and +1 kb regions; it is possible that Daxx can bind in multiple areas of the Cdk6 
promoter.  
Daxx depletion does not affect the cell cycle  
 We next attempted to determine the consequence of Daxx knockdown and 
subsequent decrease of Cdk6 levels on cellular proliferation by using HCT116 p53 +/+ 
and p53 -/- cells (Figure 4.10, A-C). Stable cell lines were created where Daxx was 
silenced using shRNA and after establishment of the stable cell lines, proliferation  
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Figure 4.9. Daxx can bind to promoter of Cdk6.  
Chromatin from HCT116 p53 +/+ cells was immunoprecipitated using anti-Daxx serum, 
anti-p53 antibody, and their respective controls. Different regions upstream or 
downstream of the Cdk6 transcription start site were amplified using region-specific 
primers and analyzed via qPCR. Samples are represented as relative input units by 
comparing fold enrichment to signal amplification of input samples. PI – pre-immune 
serum. 
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Figure 4.10. Daxx depletion and analysis of cellular proliferation. 
(A-C) Stable cells lines expressing Daxx shRNA were established in HCT116 p53 +/+ 
and HCT116 p53 -/- cells. Cell lines were analyzed for proliferation (A and B) and protein 
levels of Daxx and Cdk6 (C).  
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assays were performed. When Daxx was stably knocked down in HCT116 p53 +/+ cells, 
cellular proliferation occurred at a slower rate (Figure 4.10A); however, the same effect 
was not observed in HCT116 p53 -/- cells despite decreased levels of Cdk6 protein in 
the Daxx-depleted cells (Figure 4.10, B and C). Data from Figure 4.1 indicated that when 
Daxx was knocked down, there was a proliferative defect regardless of p53 status 
suggesting that this current result (Figure 4.10) may be cell type-specific. Based upon 
this observation, we sought to examine if Daxx depletion was able to alter the cell cycle 
profile. We used flow cytometry and propidium iodide (PI) staining to assess the cell 
cycle profiles of cells treated with control or Daxx siRNA. When Daxx was depleted in 
HCT116 p53+/+ or p53 -/- cells, we saw no difference in cell cycle profile compared to 
cells with control siRNA (Figure 4.11A). Daxx knockdown was confirmed via western 
(Figure 4.11B). These results suggest that while Daxx can affect the transcription of 
Cdk6, it is unable to elicit major changes in cellular proliferation or the duration of 
different stages of the cell cycle due to downregulation of Cdk6. 
While we were able to confirm that Daxx depletion led to lower levels of Cdk6 at 
the protein and mRNA level and that Daxx is able to bind to the promoter of Cdk6, we 
were not able to establish a physiologically relevant outcome for this effect. Future 
studies will determine the mechanism and consequence of this newly identified function 
of Daxx. A discussion of the current results can be found in chapter five.  
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Figure 4.11. Daxx silencing does not affect cell cycle profile.  
HCT116 p53 +/+ and HCT116 p53 -/- cells were treated with control and Daxx siRNA. 16 
h later, cells were stained for PI and assessed for cell cycle distribution (A). Western 
analysis confirms Daxx knockdown. Hsp70 is shown as loading control (B).  
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MATERIALS AND METHODS 
Antibodies - Antibodies for the following proteins/epitopes were purchased from the 
indicated sources: actin (A2066), tubulin (T4026), and Flag (mouse monoclonal, M2, 
(F3615) (Sigma); Daxx (M-112) p53 (DO-1) (Santa Cruz Biotechnology); Cdk6 (DCS83) 
and Cyclin D1 (DCS6) (Cell Signaling); GFP (JL-8, Clontech); Mdm2 (Ab-1,Calbiochem); 
Hsp70 (C92F3A-5, Enzo Life Sciences). Antibodies for Cdk2 and Cdk4 were kind gifts 
from the lab of Dr. J. Alan Diehl. Antibody for Rb was a kind gift from the lab of Dr. Judy 
Meinkoth. 
Microarray analysis – Note: Performed by Aaron Stonestrom. HCT116 p53 +/+ cells 
were transfected with control or Daxx siRNA and total RNA was isolated using TRIzol 
(Invitrogen). Samples were then sent to the Penn Molecular Profiling Facility for analysis. 
Briefly, total RNA was converted to first-strand cDNA using Superscript II reverse 
transcriptase primed by a poly(T) oligomer that incorporated the T7 promoter. Second-
strand cDNA synthesis was followed by in vitro transcription for linear amplification of 
each transcript and incorporation of biotinylated CTP and UTP. The cRNA products were 
fragmented to 200 nucleotides or less, heated at 99ºC for 5 min and hybridized for 16 h 
at 45ºC to microarrays. The microarrays were then washed at low (6X SSPE) and high 
(100mM MES, 0.1M NaCl) stringency and stained with streptavidin-phycoerythrin. 
Fluorescence was amplified by adding biotinylated anti-streptavidin and an additional 
aliquot of streptavidin-phycoerythrin stain. A confocal scanner was used to collect 
fluorescence signal at 3um resolution after excitation at 570 nm. The average signal 
from two sequential scans was calculated for each microarray feature. Affymetrix 
Microarray Suite 5.0 was used to quantitate expression levels for targeted genes; default 
values provided by Affymetrix were applied to all analysis parameters.  
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Quantitative RT-PCR analysis - Total RNA was isolated from cells using TRIzol 
(Invitrogen). Reverse transcription was performed using the First Strand cDNA Synthesis 
Kit (Marligen Biosciences). Primers used for Cdk6 amplification are as follows: forward 
primer 5’ – GTA ATC GTG TCT GTG TTG AG – 3’; reverse primer 5’ – TCT GCA CCC 
GCA CGC GCT TC – 3’.  
Cell culture, transfections, and western blot - All cells were obtained from the ATCC and 
maintained in Dulbecco’s modified Eagle’s medium, supplemented with 10% fetal bovine 
serum and 1% penicillin/streptomycin. To generate lentiviruses expressing control and 
Daxx shRNA, which were cloned into the pLKO.1 backbone, phoenix cells were 
transfected with pREV, pGAG, and pVSVG with either control (pLKO.1) or Daxx shRNA. 
48-72 h after transfection, the lentivirus-containing medium was used to infect HCT116 
p53+/+ and p53 -/- cells in the presence of 8 µg/mL polybrene. The infected cells were 
selected in the presence of 2 µg/ml puromycin for 4-5 days. Transient transfections were 
carried out using Lipofectamine 2000 (for DNA) or RNAiMAX (for siRNA) (Invitrogen) 
according to the manufacturer’s instructions. MG132 (20 µM) was applied to cells for 4 h, 
when required. To harvest cells, briefly, cells were scraped in IP lysis buffer and spun 
down at 17,000 x g for 15 min at 4ºC. After protein concentration was determined (Bio-
Rad), samples were resolved by SDS-PAGE. Samples were blotted with anti-Daxx 
(1:5000), anti-Cdk6 (1:200), anti-tubulin (1:5000), and anti-actin (1:5000) antibodies.  
Cellular proliferation assay – After stable cells lines expressing Daxx shRNA were 
selected and assessed for Daxx knockdown, 5,000 cells per well were seeded in 24-
well, 12-well, and 6-well plates and 6 and 10 cm dishes. Cells were seeded in duplicate 
for each condition and counted in successively larger plates to prevent them from 
reaching confluency.  
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Cell cycle analysis – After Daxx silencing for 24 h, cells were collected via centrifugation 
and washed twice with PBS and then fixed with 70% ethanol overnight at −20 °C. Cells 
were then treated with 0.1% Triton X-100 and 50 µg/mL RNase A for 30 min at 37 °C 
followed by PI staining. Cell cycle distribution was analyzed using a FACScalibur flow 
cytometer (BD Biosciences). The data were analyzed using Flow Jo software (Tree 
Star). 
Chromatin Immunoprecipitation (ChIP) – ChIP was performed using the ChIP-IT Express 
kit according to manufacturer’s instructions (Active Motif). HCT116 p53 +/+ cells were 
washed with PBS and crosslinked with a 1% formaldehyde solution for 10 min at 25ºC. 
Crosslinking was quenched by the addition of 125 mM glycine. Cells were collected 
using the provided cell-scraping solution supplemented with fresh 1 mM PMSF. Lysates 
were sonicated to generate DNA fragments with an average size below 1,000 base pairs 
and followed by immunoprecipitation with anti-Daxx serum, pre-immune serum, anti-p53 
(DO-1), an isotype-matching control and provided Protein G magnetic beads at 4ºC for 
at least 4 h or overnight. Chromatin was eluted using provided elution buffer for 15 min 
at 25ºC and crosslinks were reversed using reverse cross-linking buffer. Proteinase K 
was added to the samples and incubated at 37ºC for 1 h. qPCR was performed on the 
eluted chromatin. The primer pairs were: -1 kb forward: GCT GTG CAA TGT GTT TGT 
GTT, -1 kb reverse: ACC TCC CAG GCT CAA CCT AT; +1 kb forward: ATG GAG GGA 
TGG TTG CTA GA, +1 kb reverse: GCA CAG CTC TCT GAA AGC AA; 0 kb forward: 
CGG CCA ATT GTT GAA TGA GT, 0 kb reverse: TGG TGC TTC TTA TTT GCA ACCA; 
-700 bp forward: TAA GTG CCC TTT GCA GGT G, -700 bp reverse: TGG TGT AGC 
CTA AGC CTC CT; -300 bp forward: CTC CAC TTC CCA GGT TCA AG, -300 bp 
reverse: AAC GTG GTG AAA CCC TGT GT; p21 forward: CTG AAA ACA GGC AGC 
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CCA AG, p21 reverse: GTG GCT CTG ATT GGC TTT CTG. 
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CHAPTER 5:  DISCUSSION AND FUTURE DIRECTIONS 
 
 In the preceding chapters, I have demonstrated that Daxx is involved in p53 
regulation, protein folding, and Cdk6 modulation; an array of diverse activities that 
further add to the complex functions of Daxx within the cell and may also provide a 
biochemical unity for these functions. These findings further our understanding of the 
anti-apoptotic and transcriptional functions of Daxx while providing a novel role for Daxx 
in protein folding. The remainder of this chapter discusses the implications of these 
findings and provides ideas to expand these observations. 
The Role of Daxx in p53 Regulation 
The accumulation of p53 in response to cellular stress is highly dependent upon 
the destabilization of its main negative regulator, Mdm2. The mechanism of Mdm2 
inactivation upon stress signaling is not well understood. In this section, we showed that 
Daxx is phosphorylated by ATM at Ser564 in response to DNA damage. This 
phosphorylation event hinders Daxx association with Mdm2 allowing for destabilization 
of Mdm2 and subsequent p53 activation (Figure 5.1). The stabilization of Mdm2 by the 
Daxx S5645A mutant is Hausp-dependent, confirming our previous study where wild-
type Daxx mediated stabilization of Mdm2 was Hausp-dependent (Tang, Qu, et al, 
2006).  
 ATM is activated upon DNA damage and leads to the phosphorylation of various 
substrates either directly or via activation of downstream kinases. We have discovered 
Daxx as a novel substrate of ATM. The finding that ATM not only phosphorylates Mdm2 
and p53 in times of cellular stress, but also their upstream regulator, Daxx, indicates that 
the cell possesses an intricate signaling network to maintain genomic stability by 
activating p53. It has previously been shown that ATM-mediated phosphorylation of  
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Figure 5.1. Phosphorylation of Daxx by ATM upon DNA damage allows for p53 
activation.  
Upon DNA damage, ATM phosphorylates Mdm2 and p53. Our finding extends its 
phosphorylation activity to Daxx, as well. This event hinders the association between 
Daxx and Mdm2 thereby disrupting the Daxx-Mdm2-Hausp complex, allowing for p53 
activation.  
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Mdm2, and a related protein MdmX, reduces their affinity for Hausp, ultimately leading to 
p53 activation (Meulmeester, Maurice, et al, 2005). However, it is also known that Hausp 
deubiquitinates p53, which is important for p53 stabilization (Li, Chen, et al, 2002). 
These findings fit a model whereby the phosphorylation of Daxx upon DNA damage 
leads to dissociation of Mdm2 from itself and Hausp, allowing Hausp to direct its 
deubiquitinase activity toward p53 instead of Mdm2. Therefore, Daxx may provide 
Hausp with substrate specificity.  
A major shortcoming of the present study was the lack of a strong phenotype 
upon the introduction of the Daxx S564A mutant. It is possible that the endogenous wild-
type Daxx masked the effect of the mutant Daxx and that Mdm2 stabilization was 
already at a maximum. We attempted to circumvent this issue via the creation of stable 
cell lines that expressed shRNA against Daxx while also stably overexpressing either 
wild-type or mutant Daxx; however, we were unsuccessful in our attempts. It is possible 
that a Daxx-depleted background would allow for the effects of the mutant to become 
more apparent allowing us to see stronger downstream effects of p53 activation such as 
cell cycle arrest, apoptosis, or the induction of other p53 targets.  
The discovery that Daxx is a novel target for ATM sheds further light on the many 
signaling pathways that govern p53 activation. Daxx appears to be the central 
component of the interaction between Mdm2 and Hausp, both of which are critical 
regulators of p53. Daxx may be a promising therapeutic target for tumors that retain wild-
type p53, perhaps via the overexpression of Mdm2. The possibility cannot be excluded 
that the Daxx-Mdm2-Hausp complex not only regulates p53, but also other substrates of 
Mdm2. For example, the p53 homologs, p63 and p73 have been shown to interact with 
Mdm2 (Zdzalik, Pustelny, et al, 2010) with Mdm2 being able to inhibit p63 transcriptional 
activity and p63-mediated induction of apoptosis (Kadakia, Slader, and Berberich, 2001). 
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Thus, the stabilization of Mdm2 by Daxx not only has important implications for p53 
regulation, but also for other potential substrates of Mdm2, many of which may have 
unexplored tumorigenic properties.  
 
Future Directions 
Another responder to DNA damage, besides ATM, is ATR (ataxia telangiectasia 
and Rad3-related protein). ATR mainly responds to single-stranded DNA, while ATM 
responds to double-strand breaks in DNA or chromatin disruption (Sancar, Lindsey-
Boltz, et al, 2004). In some experiments, basal Daxx phosphorylation exists even without 
the presence of ATM or a DNA damaging agent. This can be explained in two ways: 
first, cancer cells may possess a basal amount of DNA damage leading to the activation 
of ATM causing phosphorylation of Daxx. Second, Daxx may be a substrate of ATR, as 
it is known that ATR phosphorylates p53 upon DNA damage suggesting that it may also 
target upstream regulators of p53 (Matsuoka, Ballif, et al, 2007; Tibbetts, Brumbaugh, et 
al, 1999). While ATM ablation in the study by Tang, et al did generally prevent the 
dissociation of the Daxx-Mdm2-Hausp complex upon DNA damage, it was not able to 
completely keep the complex from disrupting (Tang, Qu, et al, 2006). This indicates that 
another upstream regulator may be targeting the complex; a potential candidate is ATR. 
We could perform in vitro kinase assays with ATR to determine if ATR can directly 
phosphorylate Daxx. Since the consensus sites of ATM and ATR are the same, it is 
possible that ATM and ATR are acting at the same site to phosphorylate Daxx.  
 Besides examining the regulation of Daxx, we should also analyze how Daxx 
may affect other potential components of this complex. It is believed that Mdm2 exists 
predominantly as a heterodimer with a related protein, MdmX, and this 
heterodimerization increases the E3 activity of Mdm2 toward p53 (Kawai, Lopez-
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Pajares, et al, 2007; Linares, Hengstermann, et al, 2003). MdmX is also able to prevent 
Mdm2 from degradation (Stad, Little, et al, 2001; Tanimura, Ohtsuka, et al, 1999). MdmX 
shares a few functional characteristics with Mdm2 in that it is overexpressed in many 
tumors that retain wild-type p53, it is able to inhibit the transactivation of p53, and MdmX 
-/- mice display embryonic lethality that can be rescued by simultaneous p53 deletion 
(Danovi, Meulmeester, et al, 2004; Finch, Donoviel, et al, 2002; Migliorini, Lazzerini 
Denchi, et al, 2002; Okamoto, Taya, and Nakagama, 2009). Due to their similarity in 
function, it would be interesting to see if Daxx is able to stabilize MdmX in the same way 
as it does for Mdm2. It would also be informative to examine if Daxx is able to interact 
with MdmX and whether this interaction is affected by DNA damage. 
 During the course of this study, a report discovered many additional sites of 
ATM-mediated phosphorylation on Mdm2 (Cheng, Chen, et al, 2009). We obtained 
Mdm2 mutants from this group that were either phosphorylation-resistant (Mdm2 6A) or 
phospho-mimics (Mdm2 6D). Preliminary data indicated that Daxx could enhance the 
stability of Mdm2 6A, but not Mdm2 6D. This is in agreement with our findings that 
phosphorylation is able to interrupt the interaction between Daxx and Mdm2. It would be 
informative to see if phosphorylation events on both Daxx and Mdm2 act in a synergistic 
manner to activate p53, as the effect of the Daxx mutant alone was quite modest. 
Additionally, the binding between Daxx and Hausp is interrupted upon DNA damage; 
however, use of the Daxx S564A mutant does not prevent the dissociation of Daxx and 
Hausp (unpublished results from Dr. Jun Tang), indicating that an unidentified 
phosphorylation event on Hausp may be regulating this interaction. Determining if this 
phosphorylation occurs due to ATM signaling would provide yet another mode of p53 
regulation through the Daxx-Mdm2-Hausp complex.  
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Mdm2 activity cannot solely be controlled by Daxx, but also by the ARF tumor 
suppressor. ARF upregulation is often induced by the overexpression of oncogenes 
such as activated Ras and c-Myc (Groth, Weber, et al, 2000; Zindy, Eischen, et al, 
1998). It is known that ARF can inhibit the E3 ubiquitin ligase activity of MDM2, resulting 
in p53-mediated apoptosis or cell cycle arrest (Kamijo, Weber, et al, 1998; Pomerantz, 
Schreiber-Agus, et al, 1998; Stott, Bates, et al, 1998). ARF can also interact with Daxx 
and induce its nucleolar translocation in addition to enhancing the SUMOylation and 
ubiquitination of Daxx, without affecting its protein levels (Ivanchuk, Mondal, and Rutka, 
2008). Ivanchuk, et al showed that Daxx expression interferes with the ability of ARF to 
induce Mdm2 SUMOylation, thereby increasing the ubiquitination of Mdm2 and allowing 
for p53 activation; it is thought that inhibition of Mdm2 SUMOylation is required to 
upregulate Mdm2 self-ubiquitination (Lee, Lee, et al, 2006). The study by this group 
suggests that the interaction between ARF and Daxx influences the post-translational 
modifications of Mdm2 that are required to inhibit Mdm2-mediated p53 ubiquitination 
during cellular stress. It is possible that ARF is able to disrupt the Daxx-Mdm2-Hausp 
complex upon induction of stress signals via binding to Daxx and Mdm2 separately and 
mediating their post-translational modifications. There is a previously established ARF-
inducible U2OS cell line that we could use to test how induction of ARF affects binding 
between components of the Daxx-Mdm2-Hausp complex. Moreover, it would be 
interesting to see if ARF is able to modify or interact with Hausp, thereby modulating the 
activity of Hausp toward Mdm2.  Elucidating if ARF can affect the Daxx-Mdm2-Hausp 
complex would demonstrate that this complex is regulated by various cellular stresses 
using different mechanisms, denoting this complex as a central regulator of p53 activity.  
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Daxx as a Novel Molecular Chaperone 
Daxx has been implicated in a variety of cellular functions since its discovery. 
This study uncovers yet another potential biological role of Daxx as a molecular 
chaperone, which may serve as a way to unify the diverse functions of Daxx. Our in vitro 
studies demonstrate that Daxx can refold misfolded substrates; however, it has minimal 
activity toward larger aggregates. Consistent with the in vitro results, we saw that Daxx 
could decrease the protein levels of insoluble luciferase and preferentially bound to heat-
shocked luciferase. Additionally, Daxx showed refolding activity toward p53 both in vitro 
and in vivo.  
Our results indicate that the PAH2 and acid-rich domains of Daxx are important 
for its activity. Although, it has previously been reported that the domains denoted as 
paired amphipathic helical domains are a misnomer (Escobar-Cabrera, Lau, et al, 2010), 
we still feel that the crude structural boundary we have used defines a domain important 
for the activity of Daxx. In addition, we found that the acid-rich region of Daxx imparts 
activity to misfolded luciferase. Both regions are well conserved through evolution in 
larger mammals (Figure 5.2). These observations support an evolutionarily conserved 
function for these two domains. The creation of point mutants or small deletion mutants 
within the conserved areas of the PAH2 and/or D/E domain would allow us to test 
exactly which residues of Daxx are interacting with misfolding species. In fact, it is 
known that the binding site for p53 lies within the D/E region of Daxx (Zhao, Liu, et al, 
2004). It would be interesting to test if the aforementioned mutants would be able to 
solubilize misfolded p53. Moreover, we should assay if the DaxxΔΔ mutant or the PAH2 
and D/E domains alone can act toward p53 renaturation.  
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Figure 5.2. Examination of evolutionary conservation of the PAH2 and D/E 
domains in human Daxx.  
Alignment of human Daxx (gi|48146287) with corresponding Daxx sequences from Bos 
Taurus (gi|157278987), Mus musculus (gi|2253707), and Rattus norvegicus 
(gi|18148939) for regions around PAH2 domain (157-260) (A) and D/E region (414-505) 
(B). Alignment was done using using Clustal W2 (Goujon, McWilliam, et al, 2010; Larkin, 
Blackshields, et al, 2007). Black arrowheads indicate boundaries of regions.  
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 In all of the in vitro experiments, Daxx was used without the addition of ATP. This 
indicates that Daxx does not require energy to exert its refolding activity. The lack of 
energy coupling seen in Daxx-mediated activity is in contrast to the energy requirement 
for the traditional chaperones. While Daxx cannot suppress aggregation, and may in fact 
accelerate aggregation during heat shock, it can still recover luciferase activity to a 
greater proportion than when luciferase is alone or expressed with a canonical heat 
shock protein (Figure 3.6). This, in combination with the observation that Daxx 
accelerated denaturation of luciferase in vitro (Figure 3.4), suggests that Daxx can 
promote a reaction that is contextually favorable, not one that is energy consuming. This 
is consistent with the finding that Daxx preferentially binds to misfolded luciferase 
substrates. It is important to note that while Daxx is unable to reactivate larger luciferase 
aggregates in vitro, it is able to reactivate luciferase after heat shock in vivo when 
luciferase should be in a mostly aggregated state (Parsell, Kowal, et al, 1994). Though 
seemingly contradictory, this finding implies that either Daxx can promote the refolding of 
the misfolded, not aggregated, luciferase during recovery or that it cooperates with other 
chaperones to increase disaggregation. 
Finally, we have shown initial evidence for a role of Daxx in the regulation of p53 
distinct from what we have previously found (Tang, Qu, et al, 2006). The study by Tang, 
et al also stated that Daxx does not affect the transcription of p53, thus the effect we are 
seeing is most likely due to a post-transcriptional mechanism. We demonstrate that 
Daxx can increase levels of p53 when Mdm2 is not present, which contradicts our 
previous finding that Daxx is an indirect negative regulator of p53. We can reconcile 
these two disparate ideas by the notion that Daxx is solubilizing p53 so that Mdm2 can 
more easily target it for degradation or that Daxx is making the p53 ubiquitination sites 
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more accessible to Mdm2 via its chaperone function. The possibility cannot be excluded 
that since we used an Mdm2 null background, the effect we are seeing is not specific to 
p53 but an artifact of Daxx being able to execute its chaperone function when Mdm2 is 
not present, rather than participation in the Daxx-Mdm2-Hausp complex. A caveat of 
these experiments is that we were unable to correlate increased p53 expression with 
higher p53 transactivation. We attempted to perform reporter assays using the p53-
responsive genes p21, Noxa, and Bax; however, we saw the repression of their 
transcription upon Daxx overexpression. This is expected, as Daxx is known to be a 
transcriptional repressor that can inhibit p53 transactivation (Gostissa, Morelli, et al, 
2004), preventing us from being able to separate the effects of Daxx on transcription 
from those of p53 on transcription.  
Future Directions 
 We have discovered a heretofore unknown role for Daxx in protein folding. It is 
clear that Daxx does not act like a traditional chaperone in that it is not able to prevent 
aggregation nor is it able to promote disaggregation. Rather, Daxx behaves more as an 
unfoldase or refoldase, favoring the thermodynamically more amenable form of a 
stressed substrate. We have shown both in vitro and in vivo evidence for this 
phenomenon but many questions remain as to how Daxx exerts its chaperone activity. 
 First, we have unexpectedly observed that Daxx can accelerate the denaturation 
of proteins during heat shock. There may be precedent for this activity as studies show 
that the activity of the Hsp70 chaperones can be that of an unfoldase (Sharma, De los 
Rios, et al, 2010; Slepenkov, and Witt, 2002). Hsp70 acts an ATP-fueled polypeptide 
unfoldase that acts upon misfolded monomeric substrates and traps them in an unfolded 
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state, after which they are released from Hsp70 and allowed to spontaneously refold 
without the aid of a chaperone or input of energy (Sharma, De los Rios, et al, 2010). 
However, this system requires the input of energy for the first unfolding step, albeit the 
energy cost is quite low (about 5 molecules of ATP for unfolding of one polypeptide of 
luciferase). Following this study, the same group discovered that certain chaperonins 
(GroEL-GroES, in this case) possess the same ability to unfold denatured substrates 
and release them into solution for spontaneous folding (Priya, Sharma, et al, 2013). 
When GroEL was applied to denatured rhodanese monomers, it was able to efficiently 
unfold rhodanese in an ATP-independent manner. Subsequent spontaneous refolding 
was seen as in the case of Hsp70; however, fully efficient refolding required the addition 
of ATP and GroES. It is tempting to postulate that Daxx may act in a similar way in that 
when luciferase becomes denatured it forms misfolded species that are rapidly unfolded 
by Daxx, as demonstrated by the acceleration of loss of activity during heat shock. After 
the stress is removed and/or luciferase has reached a state from which it can be 
refolded, it is released from Daxx and transferred to another chaperone or is able to 
spontaneously refold, as seen by the reactivation of luciferase during the recovery phase 
(Figure 3.6). To determine if Daxx is an unfoldase, we can apply similar methods used in 
the two studies discussed above where they use Thioflavin-T (ThT) binding to β-sheet 
structures as a quantifiable measure for misfolding, unfolding, and refolding. Ideally, ThT 
binding should be highest in the initially denatured substrate, should be lowest upon 
addition of the chaperone, and increase, concomitantly with an increase in activity of the 
substrate, during refolding.  
Second, we would like to determine how Daxx recognizes misfolded substrates 
via the PAH2 and D/E domains. A deeper analysis of the structure of Daxx reveals many 
113 
 
disordered regions (Figure 5.3) as predicted by the Predictor of Naturally Disordered 
Regions (PONDR) VL-XT (Li, Romero, et al, 1999; Romero, Obradovic, and Dunker, 
1997; Romero, Obradovic, et al, 2001). The PAH2 and D/E domains both have predicted 
highly disordered regions. It is known that intrinsically disordered regions in small heat 
shock proteins are involved in the binding of misfolded substrates (Haslbeck, Ignatiou, et 
al, 2004; Jaya, Garcia, and Vierling, 2009; Stromer, Fischer, et al, 2004). Further, a 
recent study shows that San1, a yeast nuclear ubiquitin ligase involved in protein quality 
control, is able to bind to a variety of disparate substrates via its disordered N- and C-
terminal domains. These domains contain highly conserved small segments of order, 
which serve as substrate-recognition sites (Rosenbaum, Fredrickson, et al, 2011). They 
speculate that these disordered regions allow San1 a conformational flexibility enabling it 
to bind to many different misfolded substrates. It is possible that Daxx is working through 
a similar manner, which would not only explain the diverse array of Daxx binding 
partners, but also its ability to bind to misfolded substrates (Figure 3.13-14). The loss of 
the PAH2 and D/E domains may lead to reduced plasticity of Daxx and may explain why 
neither domain alone has activity, but together they are able to renature misfolded 
substrates. To test this, we could create many small deletions within Daxx and assess if 
the deletion mutants have any effect on association with misfolded substrates. PONDR 
predicts possible binding sites as dips in disorder; thus, it would be informative to 
correlate any binding-defective mutants with regions in the PONDR plot that may be 
potential binding regions.  
Third, determining if the acid-rich region of Daxx defines a new function for 
polyanionic entities would be enlightening as, to our knowledge, no theory has been 
proposed that puts forth a biochemical function for highly acidic regions within proteins.  
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Figure 5.3. Daxx contains regions of disorder.  
Disorder prediction of Daxx was run using PONDR (http://www.pondr.com). PAH2 
domain lies between residues 157-260. D/E region is between residues 414-505.  
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Besides the ability to confer conformational flexibility as discussed above, a polyanionic 
stretch within a protein may have a more defined function. It has previously been shown 
that proteins containing polyanionic regions have chaperone activity, and that these 
effects are specific to anionic regions, as polycationic species do not have such activity 
in vitro (Jones, Yazzie, and Middaugh, 2004; Rentzeperis, Jonsson, and Sauer, 1999). 
Further, some of the smaller heat shock proteins have flexible C-terminal regions that 
are rich in acidic amino acids, which when mutated, lead to reduced activity (Edwards, 
Kueltzo, et al, 2001; Narberhaus, 2002). Members of both the large and sHsp protein 
families interact with polyanions such as nucleic acids and tubulin (Korber, Zander, et al, 
1999; Koyasu, Nishida, et al, 1986). It is conceivable that Daxx is part of a family of acid-
rich domain containing proteins that share a similar function in terms of chaperone 
activity. Preliminary bioinformatics analysis done by another graduate student in the lab, 
Aaron Stonestrom, indicated that there are about 100 proteins in the human genome 
that contain 40 acidic amino acids within a 100-residue window. It would be informative 
to test if swapping acidic regions of those proteins with that of Daxx would still allow 
Daxx to retain its chaperone activity, providing evidence for the generality of the 
polyanionic-dependence of this activity. A similar analysis was done for the PAH2 
domain; however, no other proteins contained a homologous region signifying that this 
region is very unique and specific to Daxx. 
We would also like to know if the recently determined histone chaperone function 
of Daxx is related to the protein folding activity we have discovered. So far, the role of 
Daxx as a histone chaperone has been defined as its ability to deposit the histone 
variant H3.3 at telomeric or pericentric chromatin in cooperation with ATRX (Drane, 
Ouararhni, et al, 2010; Elsaesser, and Allis, 2010; Lewis, Elsaesser, et al, 2010). A 
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recent study has crystallized the structure of the histone-binding domain of Daxx bound 
to an H3.3-H4 dimer (Elsasser, Huang, et al, 2012). They determined several single-
point alanine mutations that led to disruption of the Daxx-H3.3-H4 complex: Ser220, 
Tyr222, Arg251, Phe317, Arg328, Asp331, and Asp349. The first three residues lie 
within the PAH2 domain and none of the point mutants are found in the D/E domain. It 
would be interesting to know how the structure of the PAH2 domain is altered in the 
presence of these mutations and if these mutations affect the chaperone activity of 
Daxx. If so, this could be a novel mode of histone chaperone activity by Daxx toward 
H3.3. Related to the histone chaperone activity of Daxx, mutations in Daxx are 
frequently found in PanNETs, often leading to an ALT phenotype. Two of these 
mutations, E465X and E448X are found in the D/E region and lead to nonsense 
mutations. Some of the other identified mutations lead to nonsense, missense, or indel 
mutations (Jiao, Shi, et al, 2011). It would be very intriguing to test these different 
mutations and their folding activity toward luciferase. If they have diminished ability to 
reactivate denatured substrates, this may provide a connection between histone 
chaperone activity, protein folding, and potentially tumorigenesis.   
The molecular chaperones of the heat shock family are so named because they 
are responsive to heat shock and other cellular stresses (Hartl, Bracher, and Hayer-
Hartl, 2011). Thus, the question arises if Daxx is also sensitive to cellular stress. Indeed, 
Daxx has previously been shown to be responsive to heat shock in that its SUMO-2 
conjugation status is increased by 24-fold upon heat shock (Golebiowski, Matic, et al, 
2009). Our results support the ability of Daxx to respond to thermal stress in that it has a 
preference for associating with non-native substrates formed by heat shock in vivo 
(Figure 3.13-14). Whether or not this preference is dependent upon the SUMOylation 
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status of Daxx would be very interesting to determine. Currently, there is no clear 
consensus as to the main function of SUMOylation in the cell, though it has been shown 
to be important for transcriptional regulation, protein stability, and apoptosis 
(Golebiowski, Matic, et al, 2009). The use of SUMO-modified Daxx in vitro may enhance 
the activity of Daxx toward denatured substrates if SUMOylation is important for the 
activity of Daxx. To corroborate these results in vivo, use of Daxx mutants that are 
unable to be SUMOylated would allow us to determine the SUMO-dependence of Daxx 
chaperone activity.  
Finally, we have discovered that Daxx is able to solubilize misfolded p53. Our lab 
has previously found that Daxx can enhance the E3 ubiquitin ligase activity of Mdm2 
toward p53 both in vitro and in vivo (Tang, Qu, et al, 2006). It is possible that Daxx is 
promoting the oligomerization of p53, an activity important for the ability of Mdm2 to 
ubiquitinate p53 (Maki, 1999). To test this, we could incubate Daxx with purified p53 and 
determine the oligomerization state of p53 via gel filtration. Determining if deletion of the 
PAH2 and/or D/E domain in in vitro ubiquitination reactions affects Mdm2 E3 activity 
may suggest a link between the protein folding activity we have found with the ability of 
Daxx to enhance the E3 activity of Mdm2 toward p53. Additionally, it is possible that the 
phosphorylation event we have found for Daxx (see chapter two) not only leads to Mdm2 
destabilization, but also allows Daxx to alter the conformation of p53 so that it can be 
better targeted by Hausp or other p53 activating proteins. This could be tested via the 
use of conformation-specific antibodies in the presence or absence of Daxx and with or 
without DNA damage. To address more therapeutic consequences of Daxx activity, it 
would be interesting to apply Daxx to conformational p53 mutants. Previous work has 
indicated that some p53 mutations found in human tumors create aggregation-prone 
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mutant p53 that co-aggregates with wild-type p53, leading to dominant-negative effects 
on wild-type p53 (Xu, Reumers, et al, 2011). It is possible that Daxx is able to relieve this 
co-aggregation, at least insofar as wild-type p53. We have tested p53 R175H, an 
aggregation-prone mutant in vitro using mammalian-purified Daxx. We saw that Daxx 
was indeed able to solubilize mutant p53; however, we have not corroborated this result 
using Daxx purified from bacteria. To determine the in vivo relevance of these findings, 
experiments could be performed where we co-express Daxx and a p53 mutant and 
fractionate the cell lysate on native gels to visualize the oligomerization state of p53. It is 
important to note that the aggregation-prone p53 mutants generally localize in the 
cytoplasm, while Daxx is a predominantly nuclear protein. Thus, it would be necessary to 
either prevent nuclear import of Daxx or mutate putative nuclear localization signals 
within Daxx so that it can associate with cytoplasmic p53.  
In summary, we have demonstrated that Daxx has the ability to refold misfolded 
proteins both in vitro and in vivo. This function may also provide a biochemical basis to 
unify the many functions of Daxx. Indeed, Daxx has an extensive list of binding partners, 
reminiscent of how Hsp70 can interact with the entire spectrum of heat-denatured 
proteins in E. coli (Mogk, Tomoyasu, et al, 1999)It is possible that Daxx acts as a 
general mediator of protein folding for a wide array of proteins; however, many questions 
remain unanswered as to the mechanism and physiological relevance of the protein 
folding activity of Daxx. Finding the answers to these questions would have great 
implications for protein quality control in the cell by determining how misfolded folded 
proteins are reactivated, by potentially defining a new class of chaperones containing 
acid-rich regions important for their activity, and by expanding histone chaperone activity 
to include protein folding. Additionally, determining if Daxx can solubilize pathogenic 
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forms of p53 would add another layer of complexity to p53 regulation by Daxx and 
provide a potential therapeutic target in cancer.  
The Role of Daxx in Cdk6 Regulation  
The cell cycle is an intricately controlled process and its regulation is necessary 
for the proper proliferation and growth of cells. Thus, understanding how its major 
effectors are controlled is important for the development of therapeutics as mutations in 
genes encoding the Cdks and cyclins have been observed in cancer (Vermeulen, Van 
Bockstaele, and Berneman, 2003). The present study showed that Daxx is able to affect 
the protein and mRNA levels of the cyclin D associated Cdk, Cdk6. We showed that 
Daxx depletion leads to lower levels of Cdk6; however, there was no robust effect on 
cellular proliferation. The effect of Daxx on Cdk6 was specific for Cdk6 as other cell 
cycle markers tested showed no difference in protein level upon Daxx knockdown. The 
effect on Cdk6 was also seen in a variety of cancer and primary cell types, suggesting 
that this was a not cell-type specific phenomenon.  
 A limitation of the current study was the presence of Cdk4 in all of the cell lines 
tested. Cdk4 and Cdk6 are generally thought to play redundant roles within the cell, 
though their mutual compensation has been controversial (Berthet, and Kaldis, 2006). 
There is only a mild phenotype associated with Cdk6 -/- mice but the phenotype is 
exacerbated in Cdk6 -/-; Cdk4 -/- embryos, as they die during development (Malumbres, 
Sotillo, et al, 2004), suggesting that Cdk4 may play a partially compensatory role when 
Cdk6 is not present. Thus, a more dramatic proliferative phenotype may be observed if 
we use cells that lack Cdk4 and then silence Daxx. If we see a strong decrease in 
proliferation, this would suggest that Daxx is a major regulator of Cdk6 and that this 
regulation has consequences for cellular proliferation.   
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 It is also important to note that other studies have determined that loss of Daxx 
leads to perturbations in normal mitotic cycling (Giovinazzi, Lindsay, et al, 2012; 
Gongora, Stephan, et al, 2001; Kwan, Lau, et al, 2013; Pan, Yi, et al, 2013). Our results 
indicate that silencing of Daxx does not lead to changes in the cell cycle profile (Figure 
4.11). Most of these studies observed very minute changes in cell cycle progression that 
were cell-type specific. It is possible that our conditions were not sensitive enough to 
elicit detectable changes in the cell cycle upon Daxx depletion.  
Future Directions 
The main challenge for us is to determine a physiologically relevant setting in 
which to study the regulation of Cdk6 by Daxx. We could examine the ability of Daxx to 
regulate Cdk6 in thymocytes as Cdk6 is thought to be the primary kinase that initiates 
pRb phosphorylation in thymocytes, due to its preferential expression in hematopoietic 
cells (Meyerson, Enders, et al, 1992; Meyerson, and Harlow, 1994). Consistent with this 
finding, Cdk6 -/- mice display defects in thymus development and reduced thymic 
cellularity (Malumbres, Sotillo, et al, 2004). Expanding upon these findings, another 
group determined that Cdk6 is required for Notch-dependent T-cell development and 
differentiation as cells without Cdk6 display maturation defects (Hu, Deshpande, et al, 
2009). Thus, it would be interesting to determine if Daxx regulates Cdk6 in thymocytes. 
Furthermore, Cdk6 downregulation has been implicated in the differentiation of various 
cell types including osteoblasts (Ogasawara, Kawaguchi, et al, 2004) and leukemic cells 
(Matushansky, Radparvar, and Skoultchi, 2003). In these instances, Cdk6 expression 
inhibits differentiation and downregulation of Cdk6 is necessary for the cells to enter 
terminal differentiation steps. It would be informative to analyze Daxx levels during the 
differentiation of these cells; if we can observe a concomitant loss of Daxx expression, 
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perhaps prior to loss of Cdk6 expression, we may be able to form a link between the 
importance of the regulation of Cdk6 by Daxx and cellular differentiation. Interestingly, 
Daxx has been shown to inhibit muscle differentiation via repression of the transcription 
factor, E2A (Gupta, Hou, et al, 2009); E2A inhibits Cdk6 gene expression (Schwartz, 
Engel, et al, 2006). This suggests a model whereby inhibition of E2A by Daxx allows for 
Cdk6 activation and inhibition of cell differentiation. We should determine the E2A-
dependence of the Daxx effect on Cdk6 via silencing of E2A in cells.   
 We were unable to go far beyond mRNA analysis (Figure 4.8) and promoter 
binding (Figure 4.9) to determine the role of Daxx in Cdk6 transcription. Since Daxx is 
not known to contain a DNA binding domain, it is likely that Daxx is indirectly binding to 
the Cdk6 promoter. There are binding sites for NF-κB, Ets, Sp1, and p300 within the 
Cdk6 promoter (Cram, Liu, et al, 2001). Daxx is known to modulate the transcriptional 
activity of NF-κB and Ets; thus, it would be informative to test if experimental reduction of 
either transcription factor would abrogate the transcriptional regulation of Daxx toward 
Cdk6.  
 Another interesting question is if Daxx works in cooperation with ATRX to control 
Cdk6 transcription. Importantly, U2OS cells do not contain endogenous ATRX (Niforou, 
Anagnostopoulos, et al, 2008), yet we were able to observe a decrease in Cdk6 levels 
upon Daxx knockdown (Figure 4.3A), suggesting that Daxx may not be completely 
dependent upon ATRX for its activity. It is still possible that in other cell lines, Daxx and 
ATRX work together to repress a subset of genes, one of which may be Cdk6. Daxx and 
ATRX are known to form a heterochromatin-remodeling complex, which is able to 
regulate transcription often via recruitment to sequence-specific transcription factors that 
bind to these promoters (Tang, Wu, et al, 2004; Xue, Gibbons, et al, 2003). When ATRX 
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is tethered to DNA, it is able to repress transcription. However, ectopic expression of 
Daxx alleviates ATRX-mediated transcriptional repression via sequestration of ATRX to 
PML-NBs by Daxx (Tang, Wu, et al, 2004). It is possible that the effect we are seeing is 
partially ATRX-dependent and that ATRX can also inhibit Cdk6 transcription. 
Theoretically, when Daxx is not present, ATRX is able to repress transcription of Cdk6; 
however, when Daxx is present, ATRX is sequestered to PML-NBs, thereby alleviating 
the transcriptional repressive effects of ATRX toward Cdk6.  
Concluding Remarks 
This dissertation has examined several biological functions of Daxx. We have 
shown that Daxx is a novel substrate of ATM and that phosphorylation of Daxx by ATM 
impairs the association of Daxx and Mdm2, allowing for p53 activation. Second, we have 
shown that, depending upon the cellular context, Daxx has the ability to promote the 
denaturation or renaturation of a protein. Finally, we have identified a new transcriptional 
target of Daxx: Cdk6, a cyclin D associated kinase involved in both cellular proliferation 
and differentiation. While these findings further our knowledge regarding the intracellular 
activities of Daxx, they also raise many questions as to how and when Daxx exerts these 
activities. Creation of a conditional Daxx -/-  mouse may help answer some of these 
questions if defects in cellular functions are found and/or if these defects occur in a 
tissue-specific manner. Additionally, elucidation of the crystal structure of Daxx would 
allow us to determine how Daxx preferentially binds to misfolded species and where 
exactly this interaction occurs.  
 Its demonstrated flexibility in response to different cellular conditions forces us to 
question why the role of Daxx would be so multifunctional. It is possible that Daxx can 
mediate a set of diverse responses depending upon the needs of the cell, providing a 
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potential explanation for its extensive list of interacting partners. The novel role of Daxx 
in protein folding may also provide a biochemical mechanism to unify all these functions 
of Daxx in that Daxx can assist a wide range of proteins to reach their native 
conformation; this may be why Daxx is involved in such disparate activities. Further, 
Daxx has been implicated in a few instances of human disease; however, the role of 
Daxx in the pathogenesis of disease remains unclear. Understanding the dynamic 
nature of Daxx will help us not only to understand the basic regulation of many biological 
processes, but may also provide a basis for establishing Daxx as a valid therapeutic 
target.  
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